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DECIPHERING THE ROLE OF HSP110 CHAPERONES IN DISEASES OF
PROTEIN MISFOLDING

Unekwu M. Yakubu, B.S.
Advisor: Kevin A. Morano, Ph.D.
Molecular chaperones maintain protein homeostasis (proteostasis) by ensuring the proper
folding of polypeptides. Loss of proteostasis has been linked to the onset of numerous
neurodegenerative disorders including Alzheimer’s, Parkinson’s, and Huntington’s disease.
Hsp110 is a member of the Hsp70 class of molecular chaperones and acts as a nucleotide
exchange factor (NEF) for Hsp70, the preeminent Hsp70-family protein folding chaperone.
Hsp110 promotes rapid cycling of ADP for ATP, allowing Hsp70 to properly fold nascent or
unfolded polypeptides in iterative cycles. In addition to its NEF activity, Hsp110 possesses
an Hsp70-like substrate binding domain (SBD) whose biological roles are undefined.
Previous work in Drosophila melanogaster has shown that loss of the sole Hsp110 gene
(Hsc70Cb) accelerates the aggregation of polyglutamine-expanded human huntingtin (HTT),
the causative agent of Huntington’s disease; while its overexpression protects against polyQmediated neuronal cell death. I hypothesize that in addition to its role as an Hsp70 NEF,
Drosophila Hsp110 (Hsc70Cb) may function as a protective protein “holdase”, preventing the
aggregation of unfolded polypeptides via the SBD-β subdomain. In the process of generating
deletion mutants in Hsc70Cb to dissect the role of the SBD-β subdomain in holdase activity, I
uncovered a redundant and heretofore unknown potent holdase capacity in a 138-amino acid
region carboxyl-terminal to both SBD-β and SBD-α (henceforth called the C-terminal
extension). This sequence is highly conserved in animal Hsp110 genes and completely
absent from fungal representatives, including Saccharomyces cerevisiae SSE1. Furthermore,
the human Hsp110s, Apg-1 and Hsp105α, also contain a C-terminal extension substrate
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binding region, indicating this site may be conserved among some metazoans. Upon further
analysis, I determined C-terminal extension chaperoning is mediated by a predicted short
intrinsically disordered region (IDR) in both fly and human Hsp110s. I demonstrate for the
first time the carboxy-terminal IDRs in fly and human Hsp110s effectively prevent aggregation
of numerous substrates, including amyloidogenic peptides Aβ1-42 and α-synuclein, in vitro.
Additionally, I use the Hsc70CbΔSBD-β construct to show the C-terminal extension is essential
for fly embryonic development, and can prevent HTT aggregation in an in vivo disease model.
These data indicate Hsc70Cb modulates neurodegeneration by blocking aggregation via a
combination of its holdase and nucleotide exchange activities. Through my work I have
attributed a biological role to Hsp110 substrate binding, while bestowing molecular and
biological significance to a previously undiscovered chaperoning domain contained within the
C-terminal extension.
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Cytosolic Protein Quality Control and Regulation

Molecular chaperones are proteins that play an essential role in maintaining cellular
homeostasis. They facilitate the proper folding of nascent polypeptide chains into their native
conformations, allowing these proteins to carry-out their appropriate cellular functions (1, 2).
Likewise, molecular chaperones help maintain protein homeostasis (proteostasis) by aiding
in the assembly of macromolecular complexes and the refolding of both nascent and mature
proteins that experience misfolding when the cell undergoes stress (3). Misfolded proteins
are prone to forming aggregates that can impede cellular function and lead to the onset of
disease (4). Chaperones promote protein folding by binding to exposed hydrophobic residues
in polypeptides, minimizing intra- and intermolecular aggregation. This binding and releasing
occurs in iterative cycles until the unfolded polypeptides assume their native conformations.
Protein chaperones thus ensure nascent chains are folded into functionally viable
conformations and misfolded proteins are refolded into their native state, preventing the
formation of toxic aggregates that lead to cell death and disease.
Disruptions in proteostasis can occur when the cell is subject to physiological stressors
such as exposure to heavy metals, metabolic imbalance, nutrient deprivation, oxidative stress,
or heat shock (1). In non-stress conditions protein misfolding can occur during translation as
a nascent chain is emerging from the ribosome, and when fully synthesized unfolded
polypeptides translocate from the cytosol into organelles such as the mitochondria or
endoplasmic reticulum (1, 5, 6). Molecular chaperones are recruited to aggregated and
misfolded proteins where they play a critical role in preventing further incorporation of unfolded
proteins into established aggregates, disassemble stable aggregates, and refold proteins. In
the case of terminally unfolded proteins, molecular chaperones assist in their subsequent
removal and degradation. As misfolded proteins accumulate in the cell, unfolded protein
response systems are activated to increase chaperone abundance and activity to counteract
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protein aggregation and potential proteostatic collapse. In the cytoplasm and nucleus this
response system is referred to as the heat shock response (HSR) and in the ER it is the
unfolded protein response (UPR). Both the HSR and UPR are highly conserved from a
common ancestor of yeast and humans and under tight regulation (7–10).
Activation of the heat shock response occurs in nearly all cells in response to stress.
Safeguarding the proteome during stress requires transcriptional activation of the HSR at the
expense of other cellular processes. Activation of the HSR enhances expression of molecular
chaperones to prevent misfolding of proteins required for cell survival. During HSR activation
inhibition of ribosome biosynthesis, cell cycle arrest, and cell membrane remodeling are
enhanced to divert energy away from less immediate cellular needs and towards recovery
(11, 12). Triaging cellular resources towards the alleviation of proteotoxic stress ensures
essential proteins are available to execute their cellular functions and prevent a critical mass
of unfolded proteins from accumulating and forming toxic aggregates.

Upregulating

chaperone expression and suppression of less critical cellular process is mediated by the derepression of the transcription factor and master stress response regulator Hsf1 (3, 10, 13–
15).
Hsf1 is a multidomain protein comprised of a DNA-binding domain (DBD), leucinezipper oligomerization domain, and one or more trans-activating domains (TAD). Under nonstress conditions Hsf1 resides in the cytosol in an inactive monomeric form. During heat shock
Hsf1 relocates from the cytosol to the nucleus where it trimerizes and binds to the heat shock
element (HSE) in the promoters of heat shock protein (HSP)-encoding genes and other
cytoprotective genes (1, 2, 16, 17). Hsf1 also acts as a regulatory chaperone, preferentially
binding cytosolic Hsp70 and Hsp90 to repress chaperoning activity under non-stress
conditions. In yeast cells, four distinct cytosol-localized soluble Hsp70s are encoded by the
SSA1, SSA2, SSA3 and SSA4 genes with largely but incompletely overlapping physiological
roles. Genetic or pharmacological disruption of Hsp70 or Hsp90 activity corresponds with an
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increase of Hsf1 activity (18). Specifically, the inability of Ssa chaperones to bind the
transcription activating domains in the amino- and carboxyl-termini of Hsf1 leads to Hsf1
hyperactivity in yeast cells (14, 19).
As misfolded proteins accumulate in the nucleus and cytosol, Hsp70 dissociates from
Hsf1 and binds exposed hydrophobic residues (20, 21). This preferential binding to unfolded
proteins de-represses Hsf1 and increases transcription of molecular chaperones. With the
aid of co-chaperones Hsp40 and Hsp110, Hsp70 interacts with diverse clients to promote
proper folding in singular or repeating cycles (10, 22) (Figure 1-1). Unlike mammalian cells,
yeast possess a disaggregase chaperone Hsp104, which dismantles aggregates formed by
misfolded polypeptides. With the assistance of Hsp70 and Hsp40, Hsp104 localizes to
aggregates and resolubilizes them into singular polypeptides (23). Polypeptides released
from aggregates by Hsp104 return to the Hsp70-Hsp40-Hsp110 folding cycle where attempts
at refolding occur. Hsp90 chaperones also facilitate protein folding in an ATP-dependent
manner, by preferentially binding partially folded proteins that function as kinases, hormone
receptors, and signal transducers (24). When proteins can no longer be folded into a native
state, they are considered terminally misfolded. As such, these proteins are sequestered with
into cytoplasmic (insoluble protein deposits – IPODs) or nuclear (juxtanuclear quality control
– JUNQ) protein bodies until they are degraded (10, 25).
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Figure 1-1: Hsp70-mediated protein folding requires co-chaperones Hsp40 and Hsp110

Hsp70
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?
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Figure 1-1: Hsp70-mediated protein folding requires co-chaperones Hsp40 and
Hsp110. Hsp70-mediated protein folding requires the activity of J-domain Hsp40 and
nucleotide exchange factor Hsp110. Hsp40 (green) delivers unfolded or partially folded
substrate (pink) to Hsp70 (blue). Hsp40 stimulates Hsp70 ATP hydrolysis which allows for
substrate binding. Hsp110 facilities nucleotide release and promotes substrate release by
allowing ADP dissociation from Hsp70 which is coupled with substrate liberation.
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Hsp70 Folding Machinery

Heat shock proteins (HSPs) are a group of ubiquitous and highly conserved molecular
chaperones with homologs present in all organisms studied. In eukaryotic cells HSPs are
readily expressed in the cytosol, nucleus, and the endoplasmic reticulum (ER) and
mitochondria organelles. Heat shock proteins were first identified in Drosophila melanogaster
(fruit fly) when it was observed that heat stress results in chromosomal puffing, due to the
heavy transcriptional induction of HSPs (26). While most HSPs are constitutively expressed,
exposure to numerous physiological stressors trigger activation of the HSR and increased
HSP expression (10). Initial nomenclature grouped HSP families by the relative molecular
weight of its members (i.e. Hsp70s, Hsp40s, Hsp90s); only after genetic and phylogenetic
analysis were HSPs further categorized by their cellular functions and localization. Members
of HSP families retain a large degree of sequence conservation and structurally homology,
even between divergent species (27).
Heat shock protein 70 (Hsp70) is the preeminent folding chaperone of the Hsp70
subfamily of molecular chaperones. Hsp70 is highly induced during stress through the HSR
and promotes the folding of nascent polypeptides by binding to exposed hydrophobic residues
as the nascent chain emerges from ribosome both in the cytosol and along the endoplasmic
reticulum (ER) (Table 1-1). In addition to co-translational chaperoning, Hsp70 maintains the
folding status of mature proteins in a similar fashion, binding to hydrophobic residues when a
protein becomes partially or completely unfolded. The role of Hsp70s in de novo folding,
proteome maintenance, and delivery of terminally misfolded proteins to degradation pathways
has earned them the designation of “cradle to the grave” molecular chaperones (28).
Canonical Hsp70s have a conserved domain structure comprised of an amino-terminal
nucleotide binding domain (NBD) where ATP binding and hydrolysis occur, and a carboxylterminal substrate binding domain (SBD) connected by a short linker (22). The SBD contains
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two subdomains: SBD-β, a β-sheet sandwich serving as the putative substrate binding site,
and SBD-α, a three α-helical bundle that acts as a lid for SBD-β (29, 30). Hsp70 folding activity
requires the binding and hydrolyzation ATP.

Hsp70 NBD and SBD conformations are

allosterically coupled; once ATP binds the NBD, SBD assumes an open confirmation allowing
the binding of substrates. Client binding is coupled to ATP hydrolysis which causes the SBD
to form a closed conformation in the ADP-bound state (31).

The iterative binding and

releasing of polypeptides in an ATP-dependent manner results in the appropriate folding of
polypeptides.
In yeast there are two classes of cytosolic Hsp70 chaperones, Ssa (Ssa1-4) and Ssb
(Ssb1-2). Ssa1-4 are cytosolic Hsp70s of which Ssa1/2 are constitutively expressed, while
Ssa3/4 are stress inducible. Ssb1/2 are compartment-bound Hsp70s, anchored to ribosomes
and assisting in the folding of nascent polypeptide chains during translation. While Ssb is
non-essential, it is highly expressed during cell growth and protein synthesis to promote de
novo protein folding. The expression of Ssa chaperones can compensate for the loss of Ssb
in yeast cells, but loss of all functional Ssa chaperones is lethal (32). Unlike SSA genes,
genes encoding SSB are downregulated when the heat shock response is activated, likely
due to the corresponding downregulation of ribosome biosynthesis during stress (33).

8

Table 1-1: Molecular chaperones homologues in yeast and human

Class

Human

Yeast

Localization

Function

Hsp110

Apg-1/2,

Sse1,2

cytosolic

Nucleotide exchange factor for

cytosolic

Hsp70; in vitro anti-aggregation

Hsp105α

(9, 34)
Hsp100

-

Hsp104

cytosolic

Disaggregase (23, 35)

Hsp90

Hsp90α

Hsc82

cytosolic

Maturation of cell cycle and signal
transduction proteins (24)

Grp94

-

ER – lumen

Proper folding of secreted and
membrane proteins (36)

Hsp70

Hsc70/Hsp70 Ssa1,2,3,4

cytosolic

Protein folding (1)

-

Ssb1,2

ribosomal

Co-translational protein folding (9)

BiP/Grp78

Kar2

ER

Protein folding; UPR activation
(37)

Hsp70L1

Ssz

ribosomal

Co-translational

protein

folding

(38)
Hsp60

Hsp60

Hsp60

Mitochondrial Chaperonin; promotes folding of
imported polypeptides (39)

Hsp40

Hdj2/DnaJA1

Ydj1

cytosolic

ATPase activator; recognition of
misfolded polypeptides (40, 41)

Hdj1/DnaJB1

Sis1

cytosolic

ATPase

activator;

misfolded

delivers

substrates

for

degradation (40, 42)
ER-

Calnexin

Cne1

ER

refolding

specific
HSF

of

mono-glycosylated

polypeptides (43)
Calreticulin

-

ER

re-glycosylation and refolding (43)

Hsf1,2,3,4

Hsf1

cytosolic

Master regulator of the HSR;

nuclear

Heat shock transcription factor
(1)
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Hsp70-mediated folding is facilitated by a number of key co-chaperones, J-proteins
and nucleotide exchange factors (NEFs) of the Hsp40 and Hsp110 classes, respectively. In
the absence of these co-chaperones Hsp70 activity is halted due to low intrinsic ATPase
activity and ADP dissociation (44). The presence of Hsp40s and nucleotide exchange factors
expand the client diversity of Hsp70 and allow for rapid and promiscuous binding and folding
of polypeptides. Hsp40 promotes ATP-hydrolysis by interacting with the Hsp70 nucleotide
binding domain, inducing a conformational change necessary for ATP-hydrolysis (45).
Nucleotide exchange factors assist Hsp70-mediated folding by allowing the rapid dissociation
of ADP from the nucleotide binding pocket of Hsp70 (Figure 1-2). Unlike Hsp40s, NEFs are
not a closely related family of chaperones.

The three dominant classes of eukaryotic

nucleotide exchange factors are Hsp110 (Sse1/2), HspBP1 (Fes1), and Bag-1 (Snl1) (3).
Nucleotide exchange factors interact with the Hsp70 NBD to cause a conformational change
that releases ADP, which coincides with substrate release (46, 47).

Once a new ATP

molecule binds the NBD, the Hsp70 folding cycle restarts.
Hsp40 chaperones are also referred to as J-domain chaperones because of their
homology to DnaJ, a DnaK (Hsp70) co-chaperone first discovered in Escherichia coli (45).
Hsp40s are structurally related class of chaperones which can be categorized into three
subgroups: I, II, III. The general domain architecture of I and II J-proteins is as follows: Jdomain, glycine/phenylalanine (G/F)-domain, carboxyl-terminal domain (CTD) 1, CTD2, and
dimerization domain (30, 48) (Figure 1-3). Distinguishing group I and II J-proteins is the
presence of a zinc finger-like domain within the CTD1 of group I. The canonical domains of
group I and II J-proteins are shared, while group III is more divergent, with the J-domain being
the only region of conservation (49).

Contained within in the J-domain is a conserved

histidine-proline-aspartic acid (HPD) sequence that allows J-proteins to interact with Hsp70s.
Interactions between the Hsp70 NBD and the HPD motif allow for activation of Hsp70 ATPase
activity (45). Coincident with stimulating ATPase activity, Hsp40 co-chaperones also scan for
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misfolded proteins, which they bind via the J-domain and deliver to Hsp70 for refolding (50–
52).
In yeast cells Ydj1 and Sis1 are the most abundant cytosolic Hsp40s. Ydj1 is a group
I Hsp40 and homolog of human J-domain, Hdj2. Loss of Ydj1 leads to slow growth phenotype
at 25˚C and lethality during heat shock (53). Ydj1 has been shown to protect nascent protein
kinases from degradation in concert with Ssa, a function that cannot be carried out by
overexpression of Sis1 (54). Sis1 is a group II Hsp40 homologous to the mammalian protein
DNAJB1. Unlike Ydj1, Sis1 is essential for yeast growth and viability. When overexpressed,
Sis1, but not Ydj1, can enhance the HSR when poly-glutamine expanded human huntingtin
(mHTT) is expressed in yeast cells. Sis1 accomplishes this by shuttling soluble mHTT into
condensates and recruiting Ssa to this site, re-localization of Ssa allows for de-repression of
Hsf1 (55). Sis1 has also been shown to suppress the aggregation of TDP-43 in a yeast model
of amyotrophic lateral sclerosis (ALS) in an indirect manner, but the exact mechanism by
which this happens remains unknown (56). A recent study indicates Sis1 directly regulates
the HSR by re-localizing to the nucleolar periphery and cytosol thereby titrating Hsp70 away
from Hsf1, allowing de-repression of the HSR (57).

Despite functional similarity when

associating with Hsp70s, Hsp40s have unique interactions with substrates leading to
divergent roles within the proteostatic network.

11

Figure 1-2: Crystal structure of yeast Sse1p (Hsp110) in complex with human Hsc70
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Figure 1-2: Crystal structure of yeast Sse1p (Hsp110) in complex with human Hsc70.
Yeast Hsp110, Sse1, engages in nucleotide exchange with human Hsc70 through
interactions in the NBD and SBD-α subdomain. Ribbon structure of Sse1, is depicted in
gold, orange, and yellow. Hsp70, Hsc70, is shown in green. This crystal structure was
obtained from Protein Database Base (PDB: 3C7N) from Schuermann et al. 2008 and
imaged using Chimera; PDB: 3C7N (29, 325).
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Figure 1-3: DnaJ dimeric structure and substrate binding mechanism
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Zinc-fingers

Figure 1-3: DnaJ dimeric structure and substrate binding mechanism. A. DnaJ from
T. thermophilus in dimeric form with highlighted domains: magenta: J-domain; yellow:
HPD-motif within the J-domain; green: poly-Proline linker; orange: glycine/phenylalanine
domain; teal: carboxyl terminal domains 1 and 2; red: dimerization domain. PDB: 4J80
(326). B. Ydj1 monomer (gold) co-crystal with peptide substrate, GWLYEIS (teal). PDB:
1NLT. (327)
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Nucleotide exchange factors facilitate Hsp70 activity by promoting the disassociation
of ADP from the Hsp70 nucleotide binding pocket. This disassociation allows Hsp70 to
release bound substrate and frees the NBD to bind a new ATP molecule and restart the folding
cycle. In bacterial cells there is only one class of NEFs Gro-P like gene E or GrpE. While
GrpE is conserved in the eukaryotic mitochondria, the cytosol possess three divergent classes
of NEFs: HspBP1/Sil1, BAG-domain proteins, and Hsp110/Grp170 (58). All known eukaryotic
NEFs induce Hsp70 ADP dissociation in a similar way, by forcing an open conformation in the
Hsp70 NBD via interactions with the I and IIB lobes (46, 58).
HspBP1, (the ER homolog is Sil1), is an armadillo-type NEF with an unstructured
amino-terminal release domain (RD) followed by four armadillo repeats in the carboxylterminus (59, 60). Like other NEFs, HspBP1 interacts with lobe IIB of the Hsp70 NBD to
induce ADP dissociation. HspBP1 and its yeast homolog Fes1 have also been shown to
induce substrate release in Hsp70 via the RD. The RD acts as a substrate mimic, interacting
with the Hsp70 SBD and competing with substrates for binding, this function is essential to
HspBP1/Fes1 activity in vivo (60). In yeast, Fes1 is essential for routing terminally misfolded
proteins to the ubiquitination pathway and eventual degradation by the proteasome (61). A
yeast model of mHTT aggregation reveals loss of Fes1 causes defects in inclusion body
formation (62).
Bcl-2 associated athanogene (BAG-1) is a 13-kDa chaperone first found to associate
with the anti-apoptotic protein Bcl-2 to promote cell survival. A crystal structure of BAG-1
reveals the protein contains three α-helices (BAG domain) that interact with Hsp70 at the I
and IIB lobes of the NBD (63). The BAG-domain proteins are the most diverse family of NEFs,
containing five (Bag-1 to -5) members all possessing different structural components outside
of the shared BAG-domain (58). Bag-1 contains a ubiquitin-like domain, allowing Bag-1 to
interact with misfolded proteins and aiding the transfer of substrates from Hsp70 to CHIPmediated degradation (64).
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Hsp110, encoded by SSE1 (constitutive) and SSE2 (stress induced) in yeast, is the
most abundant NEF, representing one-tenth of the total Hsp70-like complement in cells and
the third most abundant Hsp70 member, following Hsp70 and Hsp90 (65, 66). Hsp110s
retain the classical architecture of Hsp70 with insertions in the loop between SBD-β and SBDα and at the carboxyl-terminus (34, 67) (Figure 1-4). Deletion of both copies of SSE results
in lethality, which is only partially recovered by the overexpression of NEFs Fes1 (HspBP1)
and cytosolically localized Snl1 (BAG-1) (34, 68, 69). Sse1 facilitates nucleotide exchange
by binding Hsp70 with the IIB subdomain (NBD) and three α-helical bundle (SBD-α
subdomain), with the latter acting as a stabilizer for this interaction (46, 70). Studies in yeast
reveal ATP binding, not hydrolysis, is necessary for Sse1 NEF activity (71). In addition to its
high cellular abundance Hsp110 is also distinguished by the presence of an Hsp70-like
substrate binding site. In vitro studies of eukaryotic Hsp110s show this SBD-β can bind and
prevent the aggregation of chemically or heat denatured proteins (72–74). There has yet to
be a defined biological role assigned to Hsp110 substrate binding activity. However, the
conservation of this domain in yeast and mammalian species leads us to speculate about the
potential evolutionary advantages of this region.
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Figure 1-4: Structure of canonical Hsp110s
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Figure 1-4: Structure of canonical Hsp110s. A. Crystal structure of S. cerevisiae (yeast)
Hsp110, Sse1. teal: nucleotide binding domain; purple: substrate binding domain (SBD) β;
yellow: SBD-α. B. Schematic representation of Hsp70 juxtaposed with Hsp110s. Extended
black line preceding and following SBD-α represents the extended loops within Hsp110 when
compared to Hsp70.
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Chaperones in Protein Misfolding

Prions are protein aggregates that form when specific misfolded proteins assume
highly structured, hard-to-disassemble aggregates which are then stabilized with the
assistance of molecular chaperones. The available pool of molecular chaperones in the cell
determines whether prions are seeded and passed to daughter cells or retained within the
mother cell (Figure 1-5). The extensive study of prions in yeast gives insight into the role of
Hsp70 chaperones in prion maintenance in eukaryotic cells. Ssa acts in concert with Ydj1 to
prevent Sup35 polymerization and [PSI+] propagation (75). Conversely, a different study
reveals overexpression of Ssa1 or Ssa2 has no effect on prion [PSI+], but Ssa1
overexpression did cure cells of another yeast prion, [URE3] (76). Introducing homologous
mutations into Ssa1 (Ssa1-21) and Ssa2 (Ssa2-21) results in a weakening of the [URE3] prion.
However, in that study, the Ssa2-21 strain, but not the Ssa1-21 strain, weakened [PSI+] (77).
This finding highlights how chaperones, even when they are in the same family, can have
diverging influence on misfolded substrates. The yeast disaggregase Hsp104, Sis1, and Sse1
all preferentially bind [PSI+] prions but not the Sup35 monomers from which the prion is
produced (78). These studies emphasize the importance of Hsp70 and its co-chaperones in
prion maintenance (10).
While SSA genes have evolved to promiscuously bind substrates, studies of yeast
prions show Ssa1 and Ssa2 are responsible for the propagation of [PSI+] and [URE3]
respectively (77, 79, 80). Ssa overexpression is detrimental to Hsp104 function, suppressing
disaggregase activity and allowing [PSI+] propagation (81). Ssb are a class of ribosomeassociated Hsp70s in yeast, encoded by SSB1 and SSB2 at least one copy of SSB is required
for cell viability (82). Ssb1/2 are part of the ribosome-associated complex (RAC). Within the
RAC Ssb promotes proper co-translational folding of nascent polypeptide chains emerging
from the ribosome. Due to its association with the ribosome Ssb is believed to have anti-prion
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effects; intervening with protein folding at the “cradle” to prevent early misfolding and prion
formation. Cells lacking Ssb show increased conversion from [psi-] to [PSI+] in comparison to
wild-type cells (83). The same study reveals overexpression of Ssb cures cells from [PSI+] in
an Hsp104-dependent manner, a phenotype that has been shown in other studies (84). The
activity of Ssb with regard to prions is in stark contrast with what has been observed in Ssa
overexpression strains, which impede Hsp104 activity and lead to protection and propagation
(81). Providing further evidence for the protective role of Ssb is the ability of Ssb to interact
with Sup35 in both [PSI+] and [psi-] cells, whereas Ssa only interacts with Sup35 in the prion
form (78). Conversely, inactivation of the RAC rescues yeast from [PSI+] toxicity, supposedly
by freeing ribosome-associated Hsp40 (Ssz1) to assist in the proper folding of Sup35 (85).
Hsp40 co-chaperones assist in prion disassembly by recruiting Hsp70 to amyloids, the
localization of Hsp70 attracts Hsp104 which then disassembles aggregates one polypeptide
at a time (86–88). Both Ydj1 and Sis1 influence prion propagation in conflicting ways (89, 90).
Ydj1 tends to counteract rather than propagate prions in yeast. Ydj1 protects against [RNQ+]
aggregation and toxicity through binding [RNQ+] via the Ydj1 carboxy-terminal CAAX motif
(10, 51, 91), while it inhibits [URE3] by directly interacting with Ure2, the [URE3] precursor
protein (92, 93). Sis1 has been shown to be essential for the propagation of three yeast
prions: [PSI+], [RNQ+], and [URE3] (89). In contrast to Ydj1, Sis1 is involved in the propagation
and curing of different prions. The G/F domain of Sis1, which is expendable for other cellular
functions, is required for [RNQ+] propagation (94). Conversely, Sis1 overexpression
suppresses Sup35 conversion to [PSI+] and leads to [PSI+] curing (95).
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Figure 1-5: Chaperone-mediated prion deposition
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Figure 1-5: Chaperone-mediated prion deposition. Partially folded prion precursors
spontaneously assemble into protofibrils which further act as templates for soluble proteins.
Addition of monomeric precursors to protofibrils happens exponentially until intractable
deposits are formed. Molecular chaperones assist in prion deposition by facilitating the creation
of seeding elements through stabilizing precursors that are incorporated into protofibrils.
Fragmentation of protofibrils by chaperones gives an active end that readily templates
monomers and other protofibrils, allowing rapid formation of amyloid deposits. Prions are
cleaved in an Hsp70-dependent manner with the assistance of the yeast disaggregase,
Hsp104, and Hsp110.
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Similar to de novo protein folding, NEFs facilitate prion propagation by propelling
Hsp70 nucleotide cycling.

Sse1 aids in [PSI+] formation and propagation in yeast by

accelerating Ssa and Ssb nucleotide cycling (69). Sse1 overexpression promotes [URE3]
prion formation by increasing the available pool of soluble Ure2 that alternately folds and
assumes the prion form (93). In addition to in vivo NEF activity, Sse1 promotes [PSI+]
formation in vitro by stabilizing Sup35NM folding intermediates which serve as templates for
unfolded monomers (69, 96). It is unclear whether the Sse1 SBD plays a role in prion
stabilization. Despite having a holding-competent SBD in vitro, substrate binding function
may be expendable in vivo (74, 97). In the absence of Ssa, Sse1 has been shown to localize
to [PSI+] with Hsp104, this suggests Sse1 may directly interact with formed prions (98). In the
same study loss of Sse1 coincided with the formation of longer [PSI+] prions (98). Deletion of
Sse1 and other NEFs in yeast cells expressing misfolded human huntingtin led to HTT
fibrilization and impaired targeting of HTT aggregates and misfolded monomers for
degradation (62).
In yeast disassembly of aggregates and prions is completed by a cytosolic
disaggregase, Hsp104. Hsp104 is a Hsp100 chaperone and member of the AAA+ ATPase
superfamily. Hsp104 assumes a hexameric structure, with monomers containing an aminoterminal domain (NTD), amino-terminal nucleotide binding domain (NBD1), middle domain
(MD), carboxyl-terminal NBD (NBD2), and a C-terminal domain (CTD) (99). Hsp104 threads
unfolded polypeptides through its central pore to remove them from aggregates. Peptide
translocation is coupled with ATP hydrolysis, allowing for rapid disaggregation and
resolubilization of polypeptides (100, 101). The recruitment of Hsp104 by Hsp70 and Hsp40
is required to resolubilize misfolded proteins. Cytosolic aggregates are recognized by the
NTD and misfolded protein are siphoned out one at a time in an iterative ATP-dependent
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manner (102). The fully emerged polypeptide is then shuttled to the Hsp70 machinery for
refolding.
Hsp104 activity plays a key role in prion propagation and as such should be tightly
regulated. Hsp104 hyperactivity can lead to the disassembly of prions into smaller, heritable
seeding elements that are transmitted to daughter cells during cell division (35, 103). Seeding
and transmission of these elements allow prions to be transferred to budding daughter cells
over generations (10). The M-domain likely plays a role in seed propagation due to its
coupling of ATP hydrolysis and Hsp104 disaggregation activity. Specifically, mutations in the
M-domain that stabilize the de-repressed conformation promote prion propagation by
accelerating the rate at which prions are dismantled and transmissible seeds are formed
(104). Hsp104-mediated prion disassembly and seeding has been observed when Hsp104
acts on [PSI+]; however, Hsp104 de-repression does not have the same effects on [URE3] or
[RNQ+] (105–107). In contrast, inactivation of Hsp104 activity causes prion curing by allowing
the extensive polymerization of prions to the point they become too large to be transmitted to
daughter cells and remain in the mother (108).
Mammalian cells do not have a chaperone devoted to aggregate disassembly
homologous to Hsp104 in yeast. However, a high-throughput siRNA screen revealed the
presence of two AAA+ family proteins in human cells that are hexameric in structure and
localize to aggregates similarly to Hsp104, RuvbL1 and RuvbL2 (109, 110). RuvbL1 and
RuvbL2 are homologs of the bacterial DNA helicase RuvB. RuvB was initially identified as a
player in DNA repair, acting with RuvA to facilitate the movement of Holliday junctions and
promoting branch migration in an ATP-dependent manner (111, 112). However, later studies
revealed the mammalian homologs also carry out chaperoning functions in the cell.
Specifically, RuvbL facilitates aggresome formation and aggregate disassembly in an ATPdependent manner. Additionally, contacts with monomeric amyloid β (Aβ), insulin, and Aβ
fibrils strongly stimulate RuvbL ATPase activity, suggesting RuvbL directly interacts with and
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modulates protein aggregates (109). Despite its interactions with unfolded proteins and
aggregates RuvbL members are not upregulated during heat shock, indicating they are not
under the regulation of HSEs or Hsf1, nor are they activated during HSR in a similar manner
to other canonical HSPs (10, 109).
In eukaryotic cells the Hsp70-40-110 chaperones are crucial for the disassembly of
cytosolic aggregates. Hsp110 has been found to be the main activator of the mammalian
disaggregase machine, ex vivo studies in rats show Hsp110 energizing Hsp70 and Hsp40 to
resolubilize aggregates in an ATP-dependent manner (113).

While Hsp110-mediated

nucleotide exchange greatly accelerates protein folding, this activity only mildly drives
mammalian disaggregation in the absence of an Hsp104-like disaggregase. Despite that, it
appears Hsp110 is the limiting factor in Hsp70-Hsp40-Hsp110 driven disaggregation of fibrils
and aggregates (114–116). Increasing the levels of Hsp110, but not other NEFs, accelerates
the rate at which α-synuclein fibrils are dismantled in vitro (117). Other models of human
neurodegenerative disease support overexpression of Hsp110 as a strong modulator of
protein aggregation and other disease-linked phenotypes. A mouse model of Parkinson’s
disease shows Hsp110 overexpression halts α-synuclein aggregation and prevents aggregate
spreading in vivo (118). This activity is attributed to the direct action of Hsp110 on neuronal
aggregates and Hsp110-mediated increases in proteostatic capacity.

Mouse and squid

models of ALS consistently show Hsp110 prevents mutant SOD1 aggregation and promotes
survival in mice (119, 120). The role of the cytosolic folding machinery in human disease will
be elucidated later in this chapter.
Should attempts to refold cytosolic proteins fail, molecular chaperones facilitate
degradation by handing off misfolded proteins to the ubiquitin-proteasome system (UPS). The
UPS is a system by which ubiquitin molecules are covalently attached to chaperone-bound
substrates then transferred to the 26S proteasome for entry and rapid degradation (121).
Three classes of ubiquitin ligases are required for ubiquitin activation and transfer to target
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substrates: E1, E2, and E3 ligases. E1 is the ubiquitin-activating ligase, required for the
activation of ubiquitin (Ub) molecules. Activation occurs when ATP is exhausted to form a
thioester bond between E1 and Ub. Once activated, Ub is transferred to E2, the ubiquitinconjugating ligase. Ub transfer to substrates occurs repetitiously until a lengthy polyubiquitin
chain is formed and the substrate is effectively marked for proteasomal degradation. The E3
ubiquitin-protein ligases are required to mediate the transfer of polyubiquitinated substrates
to the 26S proteasome. The 35-kDa Hsp70 co-chaperone Carboxyl-terminus of Hsp70
Interacting Protein, or CHIP, is the most-studied member of the E3 ubiquitin ligases (122–
124). CHIP contains three domains: the tetratricopeptide repeat (TPR) domain, a helical
linker, also referred to as the coiled coil domain, and a carboxyl-terminal U-box domain (123).
The TPR domain is required for CHIP interactions with Hsp70 and Hsp90, while the U-box is
necessary for the recruitment of E2 ligases. The helical domain is not just a linker between
TPR and the U-box, this domain also assists in the dimerization of CHIP which is required for
its activity and ubiquitination (122).
Both Hsp70 and Hsp90 contain a conserved EEVD motif in their carboxyl-termini that
interact with the TPR-domain of CHIP (125). In vitro assays demonstrate interactions with
CHIP inhibit Hsp70 ATPase activity, thereby inhibiting substrate binding and refolding
attempts (126). NEFs assist in the delivery and release of polyubiquitinated substrates at the
26S proteasome. Bag-1 has been shown to interact with the Hsp70-CHIP complex and
connect it to the 19S subunit of the proteasome via its Ub-like domain, a connection that is
strengthened by CHIP-mediated ubiquitination of BAG-1 (63, 64). Hsp110 also assists in this
pathway, binding and connecting the Hsp70-substrate-Ub complex to the 19S subunit (127).
Once bound, Hsp110 facilitates the dissociation of ADP from Hsp70, allowing the release of
substrate. Finally, the proteasomal proteins Dsk2 and Rad23 shuttle the polyubiquitinated
substrate to the proteasome for degradation (121, 128).
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Activation of the Unfolded Protein Response

In addition to folding cytosolic proteins, HSPs also mediate folding of protein
intermediates destined for subcellular compartments like the mitochondria and ER. There are
a set of dedicated ER-localized HSPs that promote native folding on the lumen and within the
ER. The accumulation of misfolded proteins in the ER lumen triggers the unfolded protein
response (UPR), a conserved stress-response program activated by the titration of ERlocalized Hsp70 (BiP) away from key UPR sensors. De-repression of the UPR causes the
synthesis and translocation of specific transcription factors to the nucleus, initiating gene
expression of ER-specific molecular chaperones. Understanding the activation and regulation
of UPR is important, as dysregulation of in this system has been shown to accelerate the
conversion of protease-sensitive prion protein (PrPC), the lone prion forming protein in
humans, from its native state to a pathogenic conformation, PrPSC (129–131). ER stress and
extended UPR activity has also been implicated in the neuronal toxicity seen in Alzheimer’s
and Huntington’s disease (132–134).

Overall, the UPR, like the HSR, is important for

promoting cellular proteostasis and preventing destructive aggregation of prion and
neurodegenerative disease-associate proteins.
Proteins that will eventually be secreted from the cell or retained within the secretory
pathway are sent to the ER or Golgi apparatus for further folding and processing before they
mature (135). Chaperones embedded in the ER lumen are tasked with folding these proteins
and attempting to recover folding-compromised proteins. Should attempts at refolding fail,
these proteins are targeted for ER-associated degradation (ERAD). The UPR is triggered by
ER-localized sensors that are generally activated when misfolded proteins accumulate and
titrate away BiP, an Hsp70 member of the ER (136–140). There are three sensors in
mammalian cells: IRE1, PERK, and ATK6. IRE1 is conserved in yeast and human, but PERK
and ATK6 are only present in human cells (10).
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Inositol-requiring kinase one (IRE1) is a transmembrane serine/threonine kinase and
RNase that remains monomeric in non-stress conditions, but oligomerizes and activates using
trans-autophosphorylation via the serine/threonine kinase domain once misfolded proteins
begin to accumulate. Ordinarily, IRE1 is kept inactivate and monomeric through BiP binding.
When proteins misfold BiP preferentially binds them, de-repressing IRE1 and allowing
oligomerization. IRE1 activation causes the splicing a 26-basepair mRNA fragment from the
X-box-binding protein (XBP1) that acts as a transcription factor, localizing to the nucleus and
upregulating ER genes necessary for the UPR (141). In yeast the same transcriptional
activation occurs but is initiated by the Hac1 transcription factor (142). IRE1 activation is also
triggered by monomers directly binding unfolded substrates and oligomerizing via a MHC-like
domain independent of BiP. Adjacent monomers binding the same polypeptide stabilizes the
dimer, inducing the kinase and endonuclease activities of IRE1 (143). Despite ER stress and
UPR activation being implicated in prion disease, the specific role of IRE1 in these processes
remains elusive. Loss of XBP1 does not affect prion formation and propagation in mouse
models (144). Conversely, activation of IRE1α (one of two human IRE1 isomers) and its
downstream activation of the translation factor eIF2α in the substantia nigra and hippocampus
are hallmarks of Parkinson’s and Alzheimer’s diseases, respectively (131, 145, 146). In a
mouse model of Alzheimer’s disease loss of IRE1α corresponds with increased cognitive
ability and reduced accumulation of amyloid β plaques in the cerebral cortex and
hippocampus, indicating sustained UPR activation via IRE1 enhances amyloidogenesis and
disease-associated phenotypes (131).
Similar to IRE1, PKR-like ER Kinase (PERK) is activated when BiP preferentially binds
to unfolded polypeptides, leaving PERK to oligomerize and inactivate eIF2α, a eukaryotic
translation factor. In yeast cells Gcn2 is the PERK homolog and UPR regulator, repressing
elF2α activity through phosphorylation (147–152). eIF2α is a major translational initiator
whose inactivation coincides with a global repression of protein synthesis (153, 154). PrPSC
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induced toxicity was shown to activate the UPR via the PERK, but not IRE1, pathway (129).
This finding is substantiated by an Alzheimer’s disease study in which PERK pathway
hyperactivity was detected in post-mortem brain samples (132). Another study found PERK
activation enhances Hsf1 loss as a driver of Alzheimer’s phenotypes in mice and human cells.
Specifically, the combination of Hsf1 degradation and PERK-mediated UPR activation leads
to increased levels of hyperphosphorylated tau, a defining characteristic of disease (10, 133).
ATK6, activating transcription factor 6, is an ER membrane-embedded protein
activated by BiP dissociation and its subsequent translocation. When BiP dissociates form
ATK6, its Golgi localization domain is exposed allowing for re-localization from the ER to the
Golgi apparatus (136). In the Golgi, ATK6 is processed by proteases S1P and S2P, creating
a 50-kDa transcription activating fragment (TAF). The TAF leaves the Golgi apparatus and
enters the nucleus where it binds transcription factor NF-Y forming the ER stress response
factor (ERSF). The ERSF acts as a transcription factor and binds to promoters within UPR
specific genes, including BiP and the ER Hsp90, Grp94 (10, 155, 156).
When attempts to refold proteins in the ER fail, ER-associated degradation (ERAD)
and autophagy are upregulated. ERAD substrates are selected for degradation on the basis
of their folding state and glycosylation status, ubiquitinated, and reverse translocated out of
the ER into the cytosol where they are degraded by the 26S proteasome (157, 158).
Terminally misfolded proteins are recognized by the ERAD machinery via detection of
exposed hydrophobic residues and/or immature glycans. For example, for some proteins the
maturation process involves the attachment of amino-terminal sugars to peptide chains to
prevent them from being targeted to the Golgi apparatus or cytosol for degradation. The
oligosaccharyl transferase complex (OST) adds a Glc3-Man9-GlcNAc3 moiety to the nascent
chain as it is entering the ER to prevent premature processing and export. While the protein
is being imported, the lumenal Hsp70, BiP/Kar2, and its co-chaperone Sec63, aid in proper
protein folding. Once fully imported, the presence of these oligosaccharides signals to the ER
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chaperones that this protein needs to undergo processing by the calreticulin/calnexin folding
cycle (159). Calreticulin and calnexin are closely related human homologs of the ER localized
yeast chaperone Cne1 that aid in the proper folding of glycoproteins and prevent the export
of misfolded glycoproteins from the ER. Calnexin senses unfolded proteins by binding to
mono-glycosylated oligosaccharides on the N-glycoproteins and initiates refolding.
Calreticulin promotes folding by binding misfolded polypeptides in the ER and aiding in their
re-glycosylation for re-entry into the calnexin/calreticulin refolding cycle (43, 160). However,
calreticulin plays a dual role by also facilitating the degradation of misfolded proteins by not
initiating re-glycosylation, but the process by which this folding/degradation decision occurs
remains elusive (161).
ERAD clients must be polyubiquitinated before degradation by the 26S proteasome.
In yeast the Hrd1 transmembrane-bound ubiquitin ligase complex is primarily responsible for
ERAD. Yos9, in coordination with its interaction partner Hrd3, recognizes lumenal ERAD
substrates and facilitates their retrotranslocation out of the ER (162). Substrates pass through
a translocon pore powered by the AAA-ATPase Cdc48 complex and are subsequently
ubiquitinated by Ubc7 and Hrd1 (163). Ubiquitinated substrates are detected by Rad23 and
Dsk2 and “fed” to active proteasomes where they are degraded (128). Hrd1 is an especially
important component of the ERAD system, and may also have neuroprotective effects as it
inhibits neuronal apoptosis by promoting the degradation of Pael-R, a protein linked to familial
Parkinson’s disease (164, 165). Furthermore, loss of Hrd1 activity has also been linked to the
accumulation of amyloid precursor protein (APP) and the production of amyloid β (166). These
studies indicate ERAD, and specifically Hrd1 pay a role in the accumulation of proteins
associated with neurodegenerative disease.
In general, dysregulation of the UPR has been linked to faster conversion of
aggregate-prone monomers to oligomers and fibrils, suggesting cells undergoing ER stress
are more susceptible to prion formation. ER stress exacerbates the rates at which prion
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proteins aggregate in neuronal cell lines (130, 131). The expression of poly-glutamine
expanded huntingtin, the protein implicated in Huntington’s disease, induces ER stress by
inhibiting the interaction of the E3 ubiquitin ligase gp78 and VCP/p97, preventing the export
of polyubiquitinated ERAD clients to the cytosol for degradation (134). ALS-linked mutations
in Ubiquilin-2 interfere with protein degradation by failing to bind the 5S subunit of the
proteasome despite unencumbered interaction with substrates (167). Together the
accumulated evidence that perturbations in UPR and ERAD accelerate prion formation and
neurodegeneration underscore the important roles of these pathways in maintaining
proteostasis and preventing aggregate-mediated cellular toxicity.

Chaperone Regulation in Human Neurodegenerative Disease

The importance of molecular chaperones and the maintenance of proteostasis in
mitigating the effects of neurodegenerative disease has been well established in animal
models (118–120, 168). Dysregulation of proteostasis can be observed in age-related
neuropathies such as Huntington’s and Alzheimer’s diseases. Mutations in the chaperone
network have been linked to earlier onset and more severe phenotypes in neurodegenerative
disease, but mutations in heat shock proteins resulting in early disease onset are rare (169–
171). It has been hypothesized that molecular chaperones play dual, somewhat conflicting
roles in the progression of neurodegenerative diseases. On one hand, the increased stress
caused by amyloid formation energizes the chaperone response, resulting in the upregulation
of chaperones and other HSPs to protect the cell from toxicity. However, as aggregates grow
in size and complexity they cause further dysregulation of proteostasis; sequestering key
chaperones and impeding their disassociation from and efficient remodeling of amyloid fibrils
(172–174). These observations are supported by findings that HSR induction by Hsf1
becomes less robust with aging, indicating the onset and progression of age-related
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neuropathies may be initiated and exacerbated by a proteostatic network already in decline
(175).
In mouse studies, expression of mutant huntingtin causes the downregulation and
degradation of Hsf1, an increase in huntingtin aggregates, and more rapid decline in lifespan
and motor movement (176). Presumably, the premature degradation of Hsf1 in turn causes
decreased expression of HSR genes and a global reduction in cellular chaperone capacity.
Several studies have linked Hsf1 to the regulation of p53 and PGC-1α, two transcription
factors that play a role in mitochondrial function but are dysregulated in Huntington’s disease
(177–182). In a 2017 study, hsf1-/- mice exhibited a significant reduction in mitochondrial
density and greatly reduced PCG-1α expression in hepatic tissues; indicating Hsf1 activity
affects mitochondria synthesis directly through PCG-1α expression (183). In a disease state,
mutant huntingtin interacts with pathways regulating PGC-1α, leading to PGC-1α
downregulation and mitochondrial dysfunction. In contrast, evidence suggests Hsf1 regulates
p53 expression by promoting its degradation and inhibiting the activation of chaperoneindependent apoptosis through the MDM2-p53-p21 senescence pathway (184). In healthy
cells Hsf1 controls p53 activity through upregulation of αβ-crystallin, a small heat shock protein
that recruits the E3 ubiquitin ligase Fbx4 to promote p53 degradation (185). However, the
expression of mutant huntingtin promotes p53 stabilization by inhibiting the Mdm2 pathway.
p53 then upregulates Fbxw7 expression which results in increased Hsf1 ubiquitination and
degradation (186). In turn, lower levels of Hsf1 were found to coincide with reduced PGC-1α
expression, resulting in mitochondrial dysfunction, oxidative stress and global diminution in
HSR gene expression and available molecular chaperones, all of which potentially
exacerbates huntingtin fibrilization and related toxicity (123). Another consideration is whether
Hsf1 depletion and the accompanying decrease in mitochondrial function reduces the
available pool of ATP causing slower Hsp70-mediated protein folding, thereby advancing the
disease state.
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Accumulation of toxic protein species may also deplete cellular chaperone reserves.
In a mouse model of Huntington’s disease, a steady decrease in Hsp40 and Hsp70 was
observed as the disease progressed. Interestingly, this decrease was not due to reduced
chaperone transcript levels, indicating the change in available chaperone capacity was not
the result of reduced expression but a consequence of prolonged engagement with huntingtin
fibrils (187). These observations are corroborated by a more recent study in which an array of
proteins involved in regulated protein degradation as well as chaperones such as Hsp40 were
found to preferentially interact with insoluble mutant huntingtin oligomers (188). Again, in this
case it is possible that the proteomic impairment seen in Huntington’s may be the
consequence of Hsp40 sequestration having a rate-limiting effect on Hsp70 activity.
In mouse models of Parkinson’s disease, overexpression of α-synuclein leads to the
increased expression of Hsp70, Hsp40, and Hsp27 (189). Additionally, HSPs along with αsynuclein have been shown to be a major component of Lewy bodies in samples taken from
post-mortem human patients (190–192). A complementary study of samples taken from
human tissue demonstrated a positive correlation between Triton X-100-soluble Lewy bodies
and the co-precipitation of heat shock proteins Hsp27, Hsp70, Hsp90, and Hsp40 (193).
These studies indicate HSPs are upregulated in response to α-synuclein aggregation and
suggest that they are recruited to soluble Lewy bodies – possibly to dismantle them. More
recent studies confirm the capacity of each of these chaperones to either prevent or delay the
fibrilization of α-synuclein in vivo (116, 194, 195). This phenomenon may be
pharmacologically exploitable – treatment of rats with U-133, a derivative of echinochrome,
resulted in upregulation of HSF1 and a resultant Hsf1-mediated increase in Hsp70 expression
and concomitant reduction in α-synuclein fibrils (196).
Numerous studies support the role of HSP chaperones in directly mitigating aggregate
toxicity. However, the extent to which chaperones can affect aggregation and disease
progression depends on the specific chaperone, the tissue of expression, and the type of
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disease. Post-mortem analysis of several brain regions in Alzheimer’s patients reveal tissuespecific dysregulation of Hsp60, Hsp70, Hsc71, α-crystallin B, Grp75, and Grp94. In the
temporal cortex of the Alzheimer’s samples Hsc71 and Grp75 were downregulated, whereas
α-crystallin B was more highly expressed in comparison to non-Alzheimer’s samples (197).
From the same study, Hsp60 and Hsp70 were downregulated in the parietal cortex while
Grp94 was upregulated, while in the caudal cortex Hsp70 was the only chaperone
upregulated. Despite the obvious dysregulation of HSP expression in this particular
investigation, the role each chaperone plays in Alzheimer’s pathology is unclear. More recent
studies indicate upregulation of Hsp70 mitigates the behavioral effects of amyloid β
expression. Expression of cytosolic and secreted Hsp70 promotes recovery from Aβ1-42mediated memory loss in a fruit fly model, while expression of Hsp70 had no effect on memory
in non-Aβ1-42 -expressing flies (198). Co-incubation of insect N2 cells with Hsp70 and Aβ1-42
resulted in a 50% decrease in cell mortality and lower Aβ1-42 oligomerization in comparison to
N2 cells incubated with Aβ1-42 alone (199). While Hsp70 delayed the fibrilization of amyloid β
monomers, Hsp70 had no effect on preformed Aβ1-42 oligomers (199). The chaperone Hsp90
has also been identified as a factor in Alzheimer’s disease and shown to accumulate in
affected areas of patient brains (124).
While evidence supports neuropathy-mediated dysregulation for the proteostasis
network, age-related decline in chaperone regulation also provides an ample environment for
toxic aggregates to form. Aging research using the flatworm Caenorhabditis elegans as a
model shows that accumulation of misfolded proteins occurs in an age-dependent manner
until aggregates become too occlusive to be cleared and eventually overrun the proteomic
network (200, 201). Analysis of the human proteome in the superior frontal gyrus shows
differential expression of many chaperones during aging. Specifically, the chaperone
proteome (chaperome) profiles of neurotypical aged brains exhibit repression of ATPdependent molecular chaperone networks mimicking the chaperome of brains from patients
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who succumbed to Alzheimer’s, Huntington’s or Parkinson’s disease (202). Together, these
studies support the age-related decline in proteostasis as an important driver for the onset of
neurodegenerative diseases (174, 203, 204).

Chaperones as Therapeutic Targets

Concern about an aging population has led to increased focus on searching for
effective therapeutic targets in age-related illness, particularly neuropathies such as
Alzheimer’s disease and other dementias (204–206). The role of molecular chaperones in
counteracting the deleterious effects of prion-linked neurodegeneration has been wellestablished in cell and animal models as described thus far (4, 62, 119). The connection
between molecular chaperones and neurodegeneration has led to interest in controlling
chaperone function as a therapeutic strategy to combat disease. An attractive therapeutic
target for neurodegenerative diseases is modulation of gene expression of the chaperone
network by regulation of Hsf1. In a Huntington’s disease model, expression of mutant
huntingtin resulted in the downregulation and premature degradation of Hsf1, causing
repression of the heat shock response and an accumulation of huntingtin aggregates (176).
In a Parkinson’s disease model overexpression of α-synuclein caused the degradation of Hsf1
mediated by the ubiquitin ligase NEDD4, resulting in reduced induction of the molecular
chaperones to combat α-synuclein aggregates (207). Preliminary research shows Hsf1
activation results in reduction in poly-glutamine aggregation in mammalian cells, an effect that
translates to mouse models of Huntington’s disease (208). Interestingly, the observed antiaggregation effects of Hsf1 were not mediated by upregulation of major heat shock proteins,
suggesting Hsf1 could work independently or through some other pathway to inhibit
aggregation in some disease scenarios. Similarly, a more recent study shows Hsf1 can
prevent aggregation in low potassium conditions without trimerization, and in an HSP-
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independent manner (209). The use of small molecules, natural and synthetic, to activate Hsf1
activity has also been explored for therapeutic potential (210). A recent study identified
ASS234 as a potential small molecule inducer of HSPs and Hsf1, with confirmed resultant
inhibition of amyloid β aggregation (211). Another small molecule, HSF1A, activates HSF1
through binding the cytosolic heteromeric protein chaperone complex TRiC/CCT and
disrupting the HSF1-TRiC interaction (18). One negative consequence of Hsf1 activation is
the increased expression of amyloid precursor protein (APP), the progenitor of amyloid β. The
APP-encoding gene contains an HSE site within its promoter which may lead to the formation
of more amyloid β monomers and potential aggregates (212, 213). As previously mentioned,
Hsf1 regulates the expression of heat shock proteins during cellular stress indicating it could
also work to mitigate disease pathologies by increased expression of key chaperones that
directly respond to cellular aggregates.
Activation of the Hsp70-40-110 disaggregase is a potential, but as of yet unrealized,
focus of therapeutic approaches to combating aggregation in mammalian and human cells.
Unlike yeast, mammalian cells do not appear to encode a disaggregase similar to Hsp104.
However, activation of Hsp70 protein folding has been shown to dismantle chemically and
thermally instigated aggregates, especially in the presence of Hsp104 (113, 214). In contrast
to the Hsp70-Hsp40 mediated activation of Hsp104, Hsp70 and Hsp40 are insufficient for
disaggregation in metazoans. Hsp110 is required to help power disaggregation, making it an
interesting candidate for therapeutic study (113, 114, 215). Furthermore, the introduction of
non-Hsp110 NEFs into Hsp70-Hsp40 disaggregase reactions did not have any effect on
clearance of aggregates indicating Hsp110 plays a unique role in activating Hsp70-Hsp40
activity (216–218). Hsp110 has been directly implicated in the onset and progression of
numerous neurodegenerative diseases in animal and cellular models (219).
Loss of Hsp110 coincides with expedited aggregation of amyloid β and
hyperphosphorylated tau, SOD1, α-synuclein, and huntingtin proteins in their corresponding
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neuropathies (118, 119, 206, 220, 221). The overexpression of Hsp110 in HEK293 cells
expressing α-synuclein monomers and seeds showed a 50% reduction in fibrils when
compared to cells expressing α-synuclein alone (118). An RNAi screen in Drosophila cells
revealed Hsp110 to be a strong modulator of huntingtin aggregation. In the same study,
Hsp110 overexpression prevented huntingtin aggregate formation (220). In another study
using patient-derived neural cells Apg-2 (a human Hsp110) along with Hsc70 and DnaJB1
was found to suppress huntingtin aggregation and resolubilize fibrils (222). Hsp110 may
mitigate aggregation by synergizing Hsp70 and Hsp40 to prevent fibril formation; alternatively,
Hsp110 could help Hsp70 target misfolded proteins to the proteasome (127). Unlike other
NEFs, Hsp110 has a conserved Hsp70-like substrate binding domain which preferentially
binds aromatic residues and may modulate its ability to prevent aggregation of diseasecausing proteins (46, 47, 67, 73, 74). While Hsp110 has been shown to prevent protein
aggregation independently in vitro, the degree to which it can carry out this function in vivo is
unclear and requires further study (97, 223).
While small heat shock proteins do not form the core Hsp70 folding machinery, their
role in neurodegenerative diseases cannot be overstated. Hsp27, Hsp31, αA- and αBcrystallin, and Hsp20 among others have been shown to localize to amyloids and reduce
aggregation of amyloid β, α-synuclein, polyQ proteins, and tau to varying degrees (224–228).
Hsp31, the yeast homolog of human DJ-1, has been shown to influence [PSI+] propagation
in concert with Hsp104 (229). While overexpression of Hsp31 does not cure cells of [PSI+],
its expression prevents the aggregation of Sup35 precursors by inhibiting Sup35 induction to
the prion state (229). DJ-1 is a ubiquitous chaperone that has been shown to have antioxidant
properties and become activated in response to H2O2 stress (230–232). Loss-of-function
mutations in DJ-1 have also been linked to early onset Parkinson’s disease (169, 233, 234).
In yeast, Hsp31 has additionally been shown to modulate the aggregation of citrate synthase,
insulin, and α-synuclein (235). Interestingly, overexpression of Hsp31 resulted in a reduction
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of cytoplasmic α-synuclein foci and rescued yeast from α-synuclein fibril-associated toxicity
(235). Correspondingly, overexpression of human DJ-1 in rat astrocytes had a protective
effect on dopaminergic neurons expressing α-synuclein, mitigated neuronal mitochondrial
dysfunction, and combated dysfunction of chaperone-mediated autophagy (236).
Hsp27, also known as HspB1, has been shown to localize to aggregates implicated in
frontal temporal lobal degeneration, Alzheimer’s, Parkinson’s, and motor neuron diseases
making it an attractive target for therapeutic study (194, 226, 237–239). In mammalian cells
expressing aggregate-prone tau the enhanced expression of Hsp27 results in reduction in tau
aggregation and reactive oxygen species (240). In another study tau hyperphosphorylation
was induced in SH-SY 5Y neuroblastoma cells using okadaic acid followed by treatment with
Hsp27. The investigators observed reduction in both hyperphosphorylated tau species and
apoptosis triggered by abnormal aggregates (241). Hsp27 has also been shown to inhibit fibril
formation in cell lines expressing α-synuclein and SOD1, possibly due to its ability to promote
Hsp70 activity by facilitating the dissociation of Hsp70 from misfolded proteins (194, 225, 242,
243). Similarly, CPPGRD, a permeable small peptide derivative of the sHSP αA-crystallin,
was sufficient to prevent amyloid β fibril formation and apoptosis in human ARPE-19 cells
(244). Collectively, these studies indicate sHSPs have the ability to modulate fibrilization of
select proteins implicated in a wide range of neurodegenerative disorders, supporting
investigation into small molecules that may control their activity, thereby influencing disease
outcomes.
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Deciphering the role of Hsp110 in disease

As previously stated, there are three major classes of NEFs in eukaryotic cells. While
these co-chaperones perform the same general activity - lobular displacement in the NBD to
induce ADP dissociation - the presence of multiple NEF families raises the question of what,
if any, selective advantages are there to having multiple NEFs in eukaryotic cells? Unlike
Hsp40s, diversity in NEFs does not increase Hsp70 client diversity nor do they enhance
Hsp70 folding differentially. Of particular interest is the evolution of the Hsp110s, the only
class of NEFs possessing a conserved Hsp70 substrate binding site, SBD-β (58, 67). As I
have detailed above, Hsp110s have been shown to modulate protein aggregation, prion
propagation, and amyloid formation in eukaryotic species (69, 73, 74, 93, 96, 98). Numerous
animal models of human neurodegenerative disease indicate expression of Hsp110 plays a
key role in modulating disease-associated aggregation and phenotypes (118–120, 220).
However, it remains unclear what specific activity of Hsp110 modulates disease-associated
phenotypes.
In this work, I attempt to elucidate the role of Hsp110 substrate binding activity in
protein aggregation linked to human disease using Drosophila melanogaster Hsp110
(Hsc70Cb). Chapter 3 characterizes Hsc70Cb substrate binding activity and details the
process by which I attempt to disrupt this activity, while maintaining nucleotide exchange
function. The presence of a functionally redundant, previously undiscovered substrate binding
site in the far carboxyl-terminus of Hsc70Cb and human Hsp110s, Apg-1 and Hsp105α, is
detailed in Chapter 4. In Chapter 5, I explore the biological significance of substrate binding
mediated by either SBD-β and/or the novel carboxy-terminal extension in Drosophila
embryonic development and survival. Lastly, in Chapter 6, I use a Drosophila model of
Huntington’s disease to investigate the impact losing one or both substrate binding sites has
on huntingtin aggregation and disease-associated phenotypes.
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Chapter II: Materials and Methods
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METHODS AND TECHNIQUES

Plasmid Construction
Hsc70Cb cDNA was amplified using PCR and inserted into the pProEX-HTA protein
expression vector using 5’ SacI and 3’ SpeI restriction enzyme sites (Invitrogen, Carlsbad,
CA, USA). Two Drosophila NBD constructs (with or without a stop codon) were created by
PCR amplification followed by cloning into pProEX-HTA using 5’ SacI and 3’ SpeI restriction
sites. The Drosophila NBD-C-term construct was designed and ordered from Genewiz (South
Plainfield, NJ) and subcloned into pProEX-HTA using 5’ SacI and 3’ SpeI restriction sites.
Apg-1 and Hsp105α NBD-C-term constructs were created by PCR amplification of the
respective C-terminal extensions from cDNA and insertion into the nonstop Drosophila
pProEX-HTA-NBD plasmid using 5’ Spe1 and 3’ XhoI restriction sites. NBD-IDR constructs
were created by PCR amplification of Hsc70Cb and Hsp105α C-terminal IDRs, followed by
cloning into the non-stop Drosophila pProEX-HTA-NBD plasmid using 5’ SpeI and 3’ XhoI
restriction sites.

Protein Purification
BL21 Escherichia coli cells were used to express and purify all chaperones and fusion
constructs used in this study. Sub-culture of overnight inoculum was made to an OD of 0.15
in 600 mL Luria Broth with ampicillin (100 mg/mL) and grown to OD 0.6. Isopropyl β-d-1thiogalactopyranoside was added to the culture flask to a final concentration of 1 mM and
flasks were subject to shaking with aeration for 4 hr at 25˚C. Cell pellets were collected and
flash frozen until processing for immobilized affinity chromatography (iMAC). For iMAC, cells
were thawed and lysed using chemical lysis Buffer B (50 mM Tris Base - pH 7.5, 5 mM
imidazole, 2 mM MgCl2, 200 mM NaCl, 10% octylthioglucoside). Lysates were incubated with
Talon cobalt resin (TakaraBio, USA, Mountain View, CA) for 1 hr at 4˚C with top-over-bottom
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mixing. Following incubation, resin was separated from lysates using centrifugation, washed
with Buffer B and Buffer C (50 mM Tris - pH 7.5, 10 mM imidazole, 2 mM MgCl2, 600 mM
NaCl), and chaperones eluted with Buffer E (50 mM Tris - pH 7.5, 200 mM imidazole, 2 mM
MgCl2, 700 mM NaCl). Eluates were concentrated to ~500 μL, sterile glycerol (Fisher
Scientific) was added to a 10% concentration, and the sample was kept at -80°C until further
purification via size exclusion chromatography (SEC). iMAC samples were thawed on ice and
loaded into a purification column packed with 10 mL of Sephacryl S-100 (GE Healthcare)
equilibrated with 25 mM Tris-HCl, pH 7.5 100 mM NaCl buffer. Samples were eluted in the
same buffer; peak fractions were collected, sterile glycerol was added to a 5% concentration,
and 50 μL aliquots were frozen at -80°C until use.

Light scatter aggregation assay
Stock citrate synthase (Sigma-Aldrich, St. Louis, MO) and firefly luciferase solutions
were diluted to 18.7 μM using a chemical denaturing buffer (6.6 M guanidine hydrochloride,
5.5 mM dithiothreitol) and incubated for 1 hr at 25˚C before assays. Aggregation assays were
performed by incubating 200 nM denatured citrate synthase or firefly luciferase with 400 nM
of respective chaperones, chimeric chaperones, or bovine serum albumin in a refolding buffer
(25 mM Tris-HCl, pH 7.5, 100 mM NaCl) in a total volume of 180 μL in a clear-bottom 96-well
plate. An MX Synergy (BioTek, Winooski, VT) plate reader was used to obtain 320 nm
absorbance readings every 30 sec for 30 min (CS), or 90 min for firefly luciferase, at 25˚C.
Changes in absorbance were calculated by subtracting baseline absorbance at time zero from
readout absorbance at each time point. Assays were performed in technical triplicate for each
experiment and averaged for three separate experimental replicates.
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Differential Centrifugation
To quantify the amount of soluble versus insoluble protein after the aggregation
assays, 175 μL of the reaction was taken at the conclusion of the time course. This fraction
was subjected to differential centrifugation at 16,000 xg for 4 min. The supernatant (169 μL)
was removed to a new tube and the remaining pellet fraction was brought to 169 μL with
refolding buffer. Both supernatant and pellet fractions were brought to 400 μL volume with
molecular biology-grade water and 40 μL of trichloroacetic acid was added to precipitate
proteins. After a 45-min incubation samples were centrifuged at 16,000 xg for 15 min, pellets
washed with acetone, dried and resolubilized in 15 μl SDS-PAGE sample buffer and fractions
analyzed using SDS-PAGE and Coomassie staining. Amount of substrate in each fraction as
a percent of total was quantified using ImageJ software (NIH).

Thioflavin T binding assay
α-synuclein thioflavin T binding assays were performed by incubating 2 μM αsynuclein monomer (StressMarq Biosciences, Victoria, BC, Canada), 1 μM pre-formed fibrils
(StressMarq Biosciences, Victoria, BC, Canada), 4 μM of each respective chaperone, and 5
μM thioflavin T (Sigma, St. Louis, MO) in a total reaction volume of 180 μL using a 96-well
μClear bottom black plate (Greiner Bio-One, Monroe, NC). Samples were subject to excitation
at 450 nm and emission at 490 nm at 37˚C and fluorescence intensity was measured every 5
min for 24 hr using an MX Synergy microplate reader. Aβ1-42 was purchased from GenScript
USA (Piscataway, NJ), lyophilized Aβ1-42 was solubilized in 0.01M NaOH, pH 12.0. Thioflavin
T binding assays were performed by incubating 2 μM Aβ1-42, 4 μM of each respective
chaperone, and 5 μM thioflavin T in a total reaction volume of 50 μL in a 96-well μClear bottom
black plate. Fluorescence intensity measurements (ex. 450/em. 490) were taken every 5 min
for 16 hr at 37˚C using an MX Synergy microplate reader.
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Disaggregation assay
Aβ1-42 disaggregation assay was performed by incubating 2 μM Aβ1-42 and 5 μM
thioflavin T in refolding buffer in a total reaction volume of 50 μL in a 96-well μClear bottom
plate. Fluorescence intensity measurements (ex. 450/ em. 490) were taken every 5 minutes
for 20 hr at 37 ˚C using a BioTek MX Synergy microplate reader. At 20 hr, 4 μM of NBDIDRHsp105α was added and the reaction continued for an additional 6 hr.

Transmission electron microscopy
Samples were prepared by taking baseline fluorescence measurements of all
conditions and removing Aβ1-42 at T=0.

The remaining samples were measured by the

protocol detailed in the thioflavin T binding assay section after which samples were taken and
diluted to a total protein concentration of 1.0 μM. Samples were negatively stained with 1%
uranyl acetate in Tris-NaCl refolding buffer and fixed onto 400 mesh carbon film copper grids
(Electron Microscopy Sciences). TEM imaging was done at 100x magnification with a JEOL
1400 electron microscope. Representative images were used for all conditions. Measurement
of particles observed with the NBD-IDRHsp105α chimeric protein was performed using the
distance tool on pixel-calibrated images using ImageJ.

Statistical analysis
Welch’s variance t-test of unequal variance was used to analyze the mean differences
between conditions. End point measurements for each replicate in a condition were averaged
and analyzed using Prism 9 (Graphpad Software, San Diego, CA). For all time course
experiments measurements at each time point were taken and averaged and the standard
error of the mean was calculated. For the plots darker solid lines represent the calculated
mean while the light shading represents the standard error of mean for those data. For all
significance tests, *, p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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Transgenic fly lines
pUAST vectors containing Myc-mCherry tagged Hsc70Cb variants: Hsc70Cb, ΔCterm, ΔSBD-β, NBD-C-term, and NBD-only were constructed using Myc-mCherry cDNA and
Hsc70Cb cDNA or Genewiz constructs as a template. First, pUAST-Myc-mCherry plasmid
was created by PCR amplification of Myc-mCherry cDNA from pCASPER-NT-Myc-mCherry
plasmid (Dr. Sheng Zhang). 5’ EcoRI and 3’ Kpn1 restriction sites were used to insert MycmCherry into pUAST plasmid (Dr. Sheng Zhang).

Myc-mCherry-Hsc70Cb variants were

inserted into pUAST plasmid by first cloning constructs into the pProEX-HTA protein
expression plasmid. Myc-mCherry cDNA was cloned into pProEX-HTA using 5’ EcoRI and 3’
SacI restriction sites. Hsc70Cb constructs were PCR amplified and cloned into pProEX-HTAMyc-mCherry using 5’ SacI and 3’ KpnI restriction sites. Subcloning was used to insert MycmCherry-Hsc70Cb variants into pUAST plasmid using 5’ EcoRI and 3’ KpnI restriction sites.
DNA from the aforementioned pUAST-Myc-mCherry-Hsc70Cb variants was purified
and sent to GenetiVision Co. (Houston, TX) for embryonic injection and transgene selection.
P-element mediated integration was used to create transgenic lines. Purified plasmid DNA
was injected into w1118 embryos together with pπ25.7wc helper plasmid, followed by standard
transgenic procedures (245).
Once obtained, transgenic fly lines were assessed for chaperone expression by
crossing flies containing the GMR-GAL4 driver with transgenic lines to create flies with eyespecific expression of Myc-mCherry-Hsc70Cb constructs.

Transgene expression was

assessed by imaging F1 flies with an RFP channel using a SteREO Discovery V8 microscope
(Zeiss, Jena, Germany) to quantify relative expression of Myc-mCherry-Hsc70Cb variants by
assessing mCherry signal in the eye.
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Huntingtin Expression and Complementation Assays
The GAL4-UAS system was utilized to selectively express human huntingtin exon 1
(HTTex1) of varying poly-glutamine lengths (Qn) in the fly eye (GMR-GAL4>) (246, 247).
Transgenic flies containing GMR-GAL4>UAS-HTTex1-Qn were crossed with transgenic flies
harboring UAS-Myc-mCherry-Hsc70Cb variants to create flies co-expressing HTTex1Qn and
Myc-mCherry-Hsc70Cb variants under the control of a second chromosome GMR-GAL4
driver.
Huntingtin aggregation assay
For Huntingtin aggregation assays transgenic GMR-GAL4>UAS-HTTex1-Q72-eGFP
flies were mated with UAS-Myc-mCherry-Hsc70Cb variants to create flies co-expressing MycmCherry-Hsc70Cb variants and HTTex1-Q72-eGFP, in addition to endogenous expression of
Hsc70Cb. Parental flies were mated for 5 days before being moved to a new vial. F1 larvae
were incubated at 25 ˚C for a total of 10 days. Hatchlings were separated by sex and imaged
for HTT foci at 30 days old. At 30 days, male flies were imaged with the Alexa-488 channel
at 20x magnification using the Axio Imager Z2m (Zeiss, Jena, Germany).
Huntingtin-mediated neurodegeneration assay
For neurodegeneration assays transgenic GMR-GAL4>UAS-HTTex1-Q93 flies were
mated with UAS-Myc-mCherry-Hsc70Cb variants to create flies co-expressing Myc-mCherryHsc70Cb variants and HTTex1-Q93, in addition to endogenous expression of Hsc70Cb.
Parental flies were mated for 5 days before moving to a new vial. F1 larvae were incubated
at 25 ˚C for a total of 10 days. Hatchlings were separated by sex and kept until 7 days old
when they were imaged for neurodegeneration. At 7 days, male flies were imaged using
brightfield microscopy at 20x magnification to assess loss of red-eye pigmentation due to HTT
aggregation and neurodegeneration using the Axio Imager Z2m microscope (Zeiss, Jena,
Germany).

47

Table 2-1: Plasmids used in this study
plasmid

source

pProEX-HTA, His-tag protein expression vector
pProEX-HTA-Sse1

Invitrogen
[Garcia et al. 2017]

pUAST-Hsc70Ba (fly Hsp70)

Sheng Zhang

pUAST-dHsp110 (Hsc70Cb)

Sheng Zhang

pProEX-HTA-Hsc70Ba

this study

pProEX-HTA-Hsc70Cb

this study

pProEX-HTA-Hsc70CbSBD1

Veronica Garcia

pProEX-HTA-Hsc70CbSBD9

this study

pProEX-HTA-Hsc70CbSBD10

this study

pProEX-HTA-Hsc70CbSBD11

this study

pProEX-HTA-Hsc70CbSBD12

this study

pProEX-HTA-Hsc70Cb (non-stop construct)

this study

pPro-EX-HTA-Sse1-RFA

Veronica Garcia

pPro-EX-HTA-Hsc70CbRFA

this study

pProEX-HTA-Hsc70CbΔspacer

this study

pProEX-HTA-Hsc70CbΔSBS-β

this study

pProEX-HTA-Hsc70CbΔ390-493

this study

pProEX-HTA-Hsc70CbΔ396-443

this study

pProEX-HTA-Hsc70CbΔ396-465

this study

pProEX-HTA-Hsc70CbΔ399-493

this study

pProEX-HTA-Hsc70CbΔ399-549

this study

pProEX-HTA-Hsc70CbΔC-term

this study

pProEX-HTA Hsc70CbΔSBD-α ΔC-term

this study
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Table 2-1: Plasmids used in this study (continued)
plasmid

source

pProEX-HTA-Hsc70Cb SBD9ΔSBD-α ΔC-term

this study

pProEX-HTA-Hsc70Cb SBD10ΔSBD-α ΔC-term

this study

pProEX-HTA-Hsc70Cb SBD11ΔSBD-α ΔC-term

this study

pProEX-HTA Hsc70Cb SBD9ΔC-term

this study

pProEX-HTA Hsc70Cb SBD10ΔC-term

this study

pProEX-HTA Hsc70Cb SBD11ΔC-term

this study

pProEX-HTA-NBD-only

this study

pProEX-HTA-NBD-only (non-stop)

this study

pProEx-HTA-NBD-C-termHsc70Cb

this study

pProEX-HTA-NBD-C-termHsp105α

this study

pProEX-HTA-NBD-C-termApg-1

this study

pProEX-HTA-NBD-IDRHsc70Cb

this study

pProEX-HTA-NBD-IDRHsp105α

this study

pUAST-Myc-mCherry-Hsc70Cb

this study

pUAST-Myc-mCherry-Hsc70CbΔC-term

this study

pUAST-Myc-mCherry-Hsc70CbΔSBD-β

this study

pUAST-Myc-mCherry-NBD-C-term

this study

pUAST-Myc-mCherry-NBD-only

this study
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Table 2-2: Strains used in this study
strain

source

UAS-Myc-mCherry-Hsc70Cb

this study

UAS-Myc-mCherry-Hsc70CbΔC-term

this study

UAS-Myc-mCherry-Hsc70CbΔSBD-β

this study

UAS-Myc-mCherry-NBD-C-term

this study

UAS-Myc-mCherry-NBD-only

this study

GMR-GAL4 (2nd chromosome - Cyo balancer)
armadillo-GAL4; Dr (2nd chromosome)

[Hay et al. 1994]
[Sanson et al. 1996]

Sco/Cyo; Dr/TM6C

Bloomington Drosophila Stock Center

L(3)00082 (BL-11485)

Bloomington Drosophila Stock Center

L(3)S064906

University of Szeged

GMR-GAL4>UAS-HTTex1-Q93

[Zhang et al. 2010]

GMR-GAL4>UAS-HTTex1-Q72-eGFP

[Zhang et al. 2010]

GMR-GAL4>UAS-luc-RNAi

[Zhang et al. 2010]
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Chapter III:
Drosophila melanogaster Hsp110, Hsc70Cb, prevents protein aggregation in an
ATP-independent manner

NOTE: Portions of this chapter were derived from work previously published in The
Journal of Biological Chemistry (JBC). Yakubu, U. M., and Morano, K. A. (2021)
Suppression of aggregate and amyloid formation by a novel intrinsically disordered
region in metazoan Hsp110 chaperones. J. Biol. Chem. 296, 100567 (274). JBC does
not

require

permission

to

use

published

materials

in

https://www.elsevier.com/about/policies/copyright/permissions
.
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one’s

dissertation:

Introduction

Proteins require proper folding to perform their appropriate cellular activities; to this
end, molecular chaperones assist proteins in reaching native conformations necessary for
maintaining cellular function. In the absence of chaperone intervention, unfolded polypeptides
have the propensity to completely misfold or assume unstable folding intermediates that are
susceptible to aggregation. At the heart of many neurodegenerative and prion diseases is the
misfolding and subsequent aggregation of key proteins into highly energetically favorable
intermolecular fibrils that have a deleterious effect on the cell through recruitment of other
proteins into the initial aggregate or loss of function of the original protein. Huntington’s,
Alzheimer’s, and Parkinson’s diseases are human neurodegenerative disorders with
misfolding and aggregation acting as key agents of disease onset and progression. Several
animal models of human neurodegenerative disease show age-related decline in proteome
stability accelerate disease; additionally, general chaperone dysfunction is a contributing
factor to the disease state (174, 204).
The Hsp70 class of molecular chaperones aids in the de novo folding, maintenance,
and targeted degradation of proteins. Through its enzymatic activities Hsp70 mediates protein
folding by binding exposed residues of unfolded or partially folded polypeptides, allowing for
guided protein folding in the otherwise harsh environment of the cytosol. Hsp70 activity is
facilitated with the help of ATPase activators and nucleotide exchange factors of the J-domain
and Hsp110 classes, respectively. There are three major classes of NEFs in eukaryotic cells:
BAG-domain, HspBP1, and Hsp110s. The Hsp110 class of NEFs are the most abundant in
the cell, with both cytosolic and ER-localized (GRP170) versions (9, 58). Deletion of both
Hsp110-encoding genes in yeast, SSE1/2, results in lethality that cannot be compensated for
by the of expression of Fes1 (HspBP1) or an un-anchoring of the ER-bound Snl1 (BAGdomain) (248). These data indicate Hsp110s are essential to the cell in a way that cannot be
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compensated for by the expression of any other NEFs. For this reason, Hsp110 chaperones
are of interest.
Unlike the other NEFs, Hsp110 exhibits a conserved Hsp70 architecture: aminoterminal nucleotide binding domain (NBD), and substrate binding domain (SBD) connected
by a short linker. However, unlike Hsp70s, Hsp110s possess extended sequences flanking
the SBD-α subdomain, increasing their relative molecular weights into the 100 kDa range (66,
67). While the Hsp110 and Hsp70 SBDs are structurally similar, they have a relatively low
degree of sequence conservation at only 30% identity (223). These differences may explain
the divergent binding preferences of Hsp110 which favors exposed aromatic residues in
contrast to Hsp70’s preference for exposed hydrophobic residues (249).
Hsp110 co-chaperones are the only known nucleotide exchange factors to contain a
conserved Hsp70 substrate binding domain. In vitro studies of Hsp110 activity demonstrate
substrate binding activity happens in a passive, ATP-independent manner (73, 74, 97, 223).
For this reason, Hsp110 is referred to as a protein “holdase”, maintaining unfolded
polypeptides in a folding-competent state.

Hsp110 is unlike Hsp70 which is commonly

referred to as a “foldase”, utilizing ATP hydrolysis to carry out its enzymatic activity. In this
chapter I confirm the fly Hsp110 homolog Hsc70Cb prevents aggregation of the model
substrates citrate synthase and firefly luciferase in an ATP-independent manner. I also
attempt to disrupt substrate binding activity through a series of systematic mutations to later
evaluate the role of Hsp110 substrate binding activity in vivo using a fruit fly model. These
attempts were made by using homologous point mutations derived from studies of yeast Sse1,
a regulatable affinity fluorescence tag, and a series of partial or complete deletions to the
putative substrate binding domain, SBD-β (97, 250). I utilize previously established in vitro
techniques to evaluate the substrate binding capacity of full-length Hsc70Cb and numerous
substrate binding mutants I generated over the course of this study (251).
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Results

Previous studies in yeast and mammalian Hsp110s indicate members of this family
can function as protein “holdases”, preventing the aggregation of chemically or heat denatured
substrates by maintaining these unfolded polypeptides in a folding-competent state (73, 74,
97). I first established the ability of Hsc70Cb to function as a protein holdase and prevent
aggregation of a model substrate, chemically denatured citrate synthase, in a dose-dependent
manner (Figure 3-1). Adding increasing amounts of Hsc70Cb to the reaction significantly
decreased citrate synthase aggregation, as monitored by changes in light scatter. The ability
of Hsc70Cb to prevent aggregation is not unique to citrate synthase as a substrate; firefly
luciferase aggregation can also be abrogated by the addition of Hsc70Cb to the reaction
(Figure 3-2). The ability of Hsc70Cb to function in this capacity has historically been attributed
to the SBD-β subdomain. As previously stated, this region is comprised of a β-sheet sandwich
homologous to that contained within the Hsp70 substrate binding domain.

Given its

conservation in Hsp110s and structural similarity to the Hsp70 homolog, this domain is
presumed to be the substrate binding site within canonical Hsp110s. To further evaluate the
binding activity of Hsc70Cb I introduced numerous mutations in the form of residue
substitutions, an occlusive carboxyl-terminus regulatable fluorescence affinity tag, and
multiple deletions to the SBD-β subdomain.
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Figure 3-1: Hsc70Cb prevents aggregation in a dose-dependent manner
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Figure 3-1: Hsc70Cb prevents aggregation in a dose-dependent manner. A.
Schematic of Hsc70Cb domain architecture: nucleotide binding domain (green) a.a. 1-380;
linker (yellow) a.a. 381-389; substrate binding domain β (orange) a.a. 390-549; substrate
binding domain α (red) a.a. 556-665; C-terminal extension (blue) a.a. 666-804. B. 200 nM
denatured CS was incubated alone (no chaperone) or with Hsc70Cb (Hsp110) at .5x, 1x,
2x, or 4x concentration. Bolded lines are the average of three replicates for each condition
while the shaded region represents standard error of the mean (SEM). C. Endpoint
measurements of each condition were taken and divided by the no chaperone
measurement within the respective replicate and converted to relative percentage. Group
differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****,
p=0.00005.
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Figure 3-2: Hsc70Cb prevents aggregation of chemically denature firefly luciferase
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Figure 3-2: Hsc70Cb prevents aggregation of chemically denature firefly luciferase.
A. 200 nM denatured firefly luciferase was incubated alone (no chaperone) or with 400 nM
of respective chaperone/protein: Hsc70Cb or BSA. Bolded lines are the average of three
replicates for each condition while the shaded region represents standard error of the mean
(SEM). B. Endpoint measurements of each condition were taken and divided by the no
chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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To evaluate the substrate binding activity of Hsc70Cb I made several point mutations
in the SBD-β subdomain based on Phyre2 analysis of this region. Phyre2 is a structure
prediction program that identifies residues of high conservation within homologous protein
sequences (252).

The use of this software allowed the identification of several highly

conserved residues between Hsc70Cb and Sse1, corresponding to the loops between βsheets four and five – L4,5 – in SBD-β. A study of Sse1 conducted by former laboratory
member Dr. Veronica Garcia showed targeted mutations made in highly conserved residues
within SBD-β results in loss of substrate binding activity (97). Garcia introduced similar
targeted mutations to the SBD-β of Hsc70Cb to create Hsc70CbSBD1, a construct with
substitutions in the following residues: I431A, N432P, F437L, and V439A. These substitutions
are contained within the loops connecting β-sheets three and four (L3,4) of Sse1, which
corresponds to L4,5 of Hsc70Cb SBD-β (Figure 3-3). Upon testing with a previously
characterized aggregation assay, it was shown that these substitutions do not have any effect
on SBD function (Figure 3-3). Using this information, I introduced two additional point
mutations targeting residues V401 and W403 located in the first β-sheet of SBD-β, building
upon the Hsc70CbSBD1 construct created by Garcia (Figure 3-3). I created two variations of
this new construct, a “conservative” mutation plan in Hsc70CbSBD9, and a “risky” mutation with
Hsc70cbSBD10. The Hsc70CbSBD9 construct includes both V401A and W403L substitutions.
V401A was intended to preserve the neutral charge of this residue while using a smaller amino
acid to affect how this region interacts with substrates. The W403L substitution retains the
hydrophobicity at this residue, while losing the bulky tryptophan aromatic ring, a change which
could disrupt chaperone binding with substrates rich in aromatic residues by loss of pi-stacking
interactions. In contrast, Hsc70CbSBD10 introduces mutations V401S and W403S, exchanging
the hydrophobic valine and large aromatic tryptophan for serine, a small polar and uncharged
amino acid. These substitutions have the potential to disrupt binding by changing both the
size and charge of residues at these regions. In summary, the Hsc70CbSBD9 mutations retain
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the charge of the region while substituting for smaller amino acids at V401 and W403, while
Hsc70CbSBD10 mutations introduce changes to residue charge and size.
To assess the substrate binding activity of Hsc70CbSBD9 and Hsc70CbSBD10 I used a
previously established light scatter aggregation assay to measure the ability of these
chaperones to prevent the aggregation of denatured citrate synthase. The results of this
assay indicate these additional mutations do not disrupt Hsc70Cb substrate binding activity,
as the SBD9 and SBD10 Hsc70Cb derivatives were able to prevent citrate synthase
aggregation similarly to wild-type Hsc70Cb (Figure 3-3). This finding is substantiated using a
non-chaperoning protein, bovine serum albumin (BSA), in the aggregation reaction.
Introducing BSA to the reaction does not reduce aggregation, establishing aggregation
suppression is not just the consequence of a fully folded protein being present in the reactions
(Figure 3-4).
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Figure 3-3: Point mutations in Hsc70Cb SBD-β do not disrupt function
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Figure 3-3: Point mutations in Hsc70Cb SBD-β do not disrupt function. A. Schematic
of Hsc70Cb SBD-β point mutations. SBD1 (red); SBD9 and SBD10 (blue). B. Crystal
structure of point mutations made in Hsc70Cb SBD-β superimposed on crystal structure of
Sse1 SBD-β. Hsc70CbSBD1 mutations are in red: I431A, N432P, F437L, V439A.
Hsc70CbSBD9 and Hsc70CbSBD10 combine SBD1 with yellow: V401 and W403. C. 200 nM
denatured citrate synthase was incubated alone (no chaperone) or with 200 nM of
Hsc70Cb, SBD1, SBD9 or SBD10. Bolded lines are the average of three replicates for
each condition while the shaded region represents standard error of the mean (SEM). D.
Endpoint measurements of each condition were taken and divided by the no chaperone
measurement within the respective replicate and converted to relative percentage. Group
differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****,
p=0.00005.
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Figure 3-4: Non-chaperoning protein bovine serum albumin (BSA) does not prevent
CS aggregation
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Figure 3-4: Non-chaperoning protein bovine serum albumin (BSA) does not prevent
CS aggregation. A. 200 nM denatured CS was incubated alone (no chaperone) or with
400 nM Hsc70Cb or BSA. B. Endpoint measurements of each condition were taken and
divided by the no chaperone measurement within the respective replicate and converted
to relative percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **,
p=0.005; ***, p=0.0005; ****, p=0.00005. C. Following light scatter assay endpoint samples
were separated into soluble (sup) and insoluble (pel) fractions by differential centrifugation.
Numbers indicate per cent of pellet signal, as quantified using ImageJ, from Coomassiestained SDS-PAGE gel relative to combined sup plus pel signals.
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Another approach to disrupting substrate binding is making mutations in conserved
aromatic residues in SBD-β. It has been established that the aromatic residues of two
interacting peptides can form what are known as pi bonds, or pi-stacking. Pi-stacking is the
non-covalent bonding of two aromatic rings when transiently interacting in a way that stabilizes
the protein-protein contact (253). It has been shown that the side chains of phenylalanine,
tyrosine, histidine, and tryptophan amino acids participate in pi-stacking (254). The Hsc70Cb
substrate binding domain contains twelve aromatic residues, of which Phyre2 analysis
predicts phenylalanine 437 to be the most highly conserved and structurally relevant.
Substitutions at aromatic residues may counteract pi forces by removing one of the interacting
aromatic rings via deletion or substitution of aromatic ring containing residues. A study of ERlocalized Hsp70s shows Grp170, the Hsp110 homolog, preferentially binds aromatic residues,
but this binding was abolished when aromatic resides in the substrates were changed to
aspartic acid (255). It has not been confirmed that pi-stacking potentiates substrate binding
in molecular chaperones, but evidence suggested it would be a worthwhile mutation to create
given the binding preferences of Hsp110s (249).

To that end, I created two additional

substitution mutations in which F437 is replaced by either an aspartic acid or alanine residue.
These substitutions were chosen based on degree of conservation at F437 using Phyre2
(252). The F437D substitution is predicted to have a high degree of disruption to structure
and/or function of SBD-β, whereas F437A is predicted to moderately affect both. The F437
substitution was not made in isolation, it was created in the backbone of Hsc70SBD1. Upon
testing it was shown this reside did not influence SBD activities (Figure 3-5).
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Figure 3-5: Substitutions at position F437 do not disrupt substrate binding
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Figure 3-5: Substitutions at position F437 do not disrupt substrate binding. A.
Schematic of Hsc70Cb SBD11 and SBD12 point mutations. F437 is represented in green.
B. Crystal structure of point mutations from (A.) superimposed on crystal structure of Sse1
SBD-β. red: I431A, N432P, V439A. yellow: F437D/A C. 200 nM denatured citrate
synthase was incubated alone (no chaperone) or with 200 nM of Hsc70Cb, SBD11 or
SBD12. Bolded lines are the average of three replicates for each condition while the
shaded region represents standard error of the mean (SEM). D. Endpoint measurements
of each condition were taken and divided by the no chaperone measurement within the
respective replicate and converted to relative percentage. Group differences were
analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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In an alternative approach, I attempted to disrupt substrate binding activity by adding
an occlusive regulated fluorescence affinity tag (RFA-tag) to the carboxyl-terminus of
Hsc70Cb. The RFA-tag contains an amino-terminal green fluorescence protein-tag (GFP), a
di-hydrofolate reductase (DHFR) degradation domain (DD domain) derived from E. coli, and
an HA-tag. The DD domain is regulated by the addition of the folate analog trimethoprim
(TMP) (256). In the absence of TMP the DD domain remains unfolded; however, when TMP
is available the DD domain assumes a stable structure. This approach came from a 2012
paper published in Nature Communications indicating the cellular activities of Plasmodium
falciparum Hsp110 are impeded with the addition of a carboxyl-terminal RFA-tag (250).
Specifically, the presence of the DD domain is thought to be occlusive to Hsp110 activity when
unstable; impairing P. falciparum growth and thermoresistance during heat shock by blocking
the substrate binding domain of Hsp110. This conclusion was undergirded by the observed
increase in protein aggregation when the DD domain was not bound by TMP. The addition
of TMP to the reaction corresponded with a general restoration of Hsp110 activities, including
reduced protein aggregation and a restoration of wild-type growth rate. In this study, it was
not officially established whether the disruptive effects of the unregulated DD domain were
caused by a loss of substrate binding activity. Despite that, the proximity of the RFA to the
SBD indicated it could disrupt the ability of Hsp110 to bind substrates. With that in mind, I
appended an RFA-tag to the carboxyl-terminus of Hsc70Cb. Using this construct in the light
scatter assay demonstrated that attaching an unstructured DD domain to the carboxylterminus of Hsp70cb does not obstruct substrate binding (Figure 3-6).
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Figure 3-6: Carboxyl-terminal RFA-tag does not occlude Hsc70Cb substrate binding
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Figure 3-6: Carboxyl-terminal RFA-tag does not occlude Hsc70Cb substrate binding.
A. Schematic of Hsc70CbRFA binding activity in the presence or absence of trimethoprim.
B. 200 nM denatured citrate synthase was incubated alone (no chaperone) or with 200 nM
of respective chaperone: Hsc70Cb or Hsc70CbRFA. Bolded lines are the average of three
replicates for each condition while the shaded region represents standard error of the mean
(SEM). C. Endpoint measurements of each condition were taken and divided by the no
chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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Attempts to disrupt binding by targeted mutations and carboxyl-terminal tagging of the
SBD were not successful. I therefore considered other regions of interest surrounding SBDβ. Earlier works have confirmed the SBD-β as a substrate binding site in eukaryotic Hsp110s;
however, my inability to disrupt binding lead me to look at other domains of interest (72, 74,
249). It has been suggested that substrate binding is facilitated by the loops connecting βsheets and more structured segments of proteins (257). I posited that perhaps Hsc70Cb
substrate binding was occurring in a similar manner, and removal of such regions may
abrogate SBD activity. To this end, I created Hsc70CbΔspacer a construct removing residues
550-555, encoding the amino acids THGFSP, between the SBD-β and SBD-α subdomains.
In addition to removing residues 550-555, Hsc70CbΔspacer also contains the SBD1 point
mutations in SBD-β. These residues were removed with the rationale that substrate binding
may be mediated by this small and moderately conserved connector between SBD-β and
SBD-α. However, this region was not necessary for Hsp110 SBD activity (Figure 3-7).
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Figure 3-7: Removing five-amino acid spacer between SBD-β and SBD-α does not
disrupt Hsc70Cb substrate binding activity
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Figure 3-7: Removing five-amino acid spacer between SBD-β and SBD-α does not
disrupt Hsc70Cb substrate binding activity. A. Schematic of Hsc70CbΔspacer domain
architecture B. 200 nM denatured citrate synthase was incubated alone (no chaperone) or
with 400 nM of respective chaperone: Hsc70Cb or Hsc70CbΔspacer. Bolded lines are the
average of two replicates for each condition while the shaded region represents standard
error of the mean (SEM).
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My inability to disrupt SBD activity using point mutations and short deletions within the
predicted substrate binding regions lead me to move forward with a more drastic mechanism
to disrupt Hsc70Cb activity. I went on to design and purify six constructs that partially or
completely remove the SBD-β subdomain (Figure 3-8). With the guidance of Dr. Veronica
Garcia, I used Phyre2 domain prediction software and the crystal structure of Sse1 to help
make deletions that were disruptive to SBD-β without compromising the overall stability of
Hsc70Cb. To accomplish this, we removed regions in an attempt to avoid abrupt cuts within
the predicted β-sheets, instead mapping the deletions to start and end in the loops between
the SBD-β β-sheets. All six constructs were stably expressed and purified; however,
Hsc70CbΔ396-465 was not stable and aggregated alone in the light scatter assay (data not
shown). The remaining constructs were assayed as previously described and shown to not
be disruptive to SBD activity (Figure 3-9). Of significant note is Hsc70CbΔSBD-β the construct in
which the entire putative substrate binding domain is removed. This construct led me to
consider two possibilities: SBD-β is not the substrate binding region in Hsc70Cb or there is
more than one substrate binding site within the chaperone. I started with the first theory, that
Hsc70Cb is unique among Hsp110s and has a substrate binding site outside of SBD-β.
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Figure 3-8: Targeted deletions to the SBD-β subdomain
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Figure 3-8: Targeted deletions to the SBD-β subdomain. A. Schematic of Hsc70Cb
architecture indicating partial or complete deletions to the SBD-β subdomain. B. 200 ng of
purified Hsc70Cb and each SBD-β deletion mutant used in this study via 12% SDS-PAGE
stained with Coomassie Brilliant Blue. *Hsc70CbΔ396-365 was stably purified but did not
remain soluble and could not be assayed.
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Figure 3-9: Partial or complete deletion of SBD-β does not disrupt Hsc70Cb
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Figure 3-9: Partial or complete deletion of SBD-β does not disrupt Hsc70Cb
substrate binding activity. A. 200 nM denatured CS was incubated alone (no chaperone)
or with 400 nM of respective chaperone: Hsc70Cb, Hsc70CbΔSBDβ, Hsc70CbΔ390-493,
Hsc70CbΔ399-549, Hsc70CbΔ396-443, Hsc70CbΔ399-493. Bolded lines are the average of three
replicates for each condition while the shaded region represents standard error of the mean
(SEM). B. Endpoint measurements of each condition were taken and divided by the no
chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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To localize and disrupt the presumed novel substrate binding capacity of Hsc70Cb, I
created several deletion constructs in which I removed different domains and regions
carboxyl-terminal to the SBD-β: SBD-α and a region in the far carboxyl-terminal of Hsc70Cb
henceforth called the C-terminal extension. I created Hsc70CbΔC-term, a construct in which I
removed the carboxyl-terminal extension in Hsc70Cb, a region that expands beyond the SBDα lid. Originally, this region was not one of interest as it was assumed to be an extension of
the SBD-α subdomain. However, the results of the ΔSBD-β deletion mutants indicated there
may be other areas of interest outside of the SBD. Hsc70CbΔC-term was stably expressed and
purified from E. coli for in vitro screening. Upon screening it was shown that deletion of this
region alone did not disrupt substrate binding activity (Figure 3-10). Because this region did
not appear to mediate substrate binding I created Hsc70CbΔSBD-αΔC-term, a construct removing
SBD-α and the far C-terminal extension under the pretense that SBD-α contained the
substrate binding site. Since the C-terminal extension removal did not affect SBD activity, I
did not believe it was necessary to remove SBD-α in isolation and simply removing SBD-α
with the C-terminal extension was sufficient. In vitro screening reveals the removal of both
regions does not abrogate substrate binding (Figure 3-11). The same was true for the
constructs in which I combined the initial SBD-β point mutations (SBD9, SBD10, and SBD11)
with the deletions to SBD-α and the C-terminal extension (Figure 3-12). These results indicate
substrate binding is mediated, in part, by SBD-β, and the initial SBD-β substitutions were not
deleterious mutations being masked by the presence of secondary substrate binding domain.
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Figure 3-10: Removal of the far C-terminal extension does not disrupt Hsc70Cb
substrate binding activity
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Figure 3-10: Removal of the far C-terminal extension does not disrupt Hsc70Cb
substrate binding activity. A. Schematic of Hsc70CbΔC-term domain architecture. B. 200
nM denatured CS was incubated alone (no chaperone) or with 400 nM Hsc70Cb or
Hsc70CbΔC-term. C. Endpoint measurements of each condition were taken and divided by
the no chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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Figure 3-11: Removing SBD-α and the C-terminal extension does not disrupt
Hsc70Cb substrate binding activity
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Figure 3-11: Removing SBD-α and the C-terminal extension does not disrupt
Hsc70Cb substrate binding activity.

A. Schematic of Hsc70CbΔSBD-α

ΔC-term

domain

architecture. B. 200 nM denatured CS was incubated alone (no chaperone) or with 400 nM
Hsc70Cb or Hsc70CbΔSBD-α ΔC-term. C. Endpoint measurements of each condition were
taken and divided by the no chaperone measurement within the respective replicate and
converted to relative percentage. Group differences were analyzed using Welch’s t-test. *,
p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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Figure 3-12: Combining SBD-β point mutations with SBD-α and C-terminal extension
deletions does not disrupt Hsc70Cb substrate binding activity
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Figure 3-12: Combining SBD-β point mutations with SBD-α and C-terminal extension
deletions does not disrupt Hsc70Cb substrate binding activity. A. Schematic of
Hsc70CbSBD10ΔSBD-αΔC-term point mutations and domain architecture. B.200 nM denatured CS
was incubated alone (no chaperone) or with 400 nM Hsc70Cb or SBD10ΔSBD-αΔC-term. SBD1
and SBD9 were also assayed with the same results but data not shown. C. Endpoint
measurements of each condition were taken and divided by the no chaperone
measurement within the respective replicate and converted to relative percentage. Group
differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****,
p=0.00005.
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Discussion

Attempts at disrupting the putative substrate binding domain of Hsp110 member
Hsc70Cb failed. Initially, I built upon Veronica Garcia’s original Hsp70cb SBD mutagenesis
plan in which I took mutations made in the SBD-β subdomain and included two additional
mutations at conserved residues V401 and W403. Substitutions at these two residues did not
disrupt Hsc70Cb activity despite their conservation and presumed relevance in SBD-β
structure or binding activity. Furthermore, making substitutions in aromatic residues based
on published data showing substitution of aromatic residues for aspartic acid or alanine cause
disruptions in substrate-chaperone interactions did not impact Hsc70Cb.
In a more drastic approach, I decided to make deletions to SBD-β targeting large
portions of the putative substrate binding region. However, it appears partial or complete loss
of SBD-β does not abolish substrate binding activity. These results were indicative of a
different chaperoning mechanism in Hsc70Cb that either does not rely on SBD-β, or involves
SBD-β and another domain. To decipher between the two, I made a combination of deletions
to SBD-β, SBD-α, and the C-terminal extension. Deleting SBD-α and the C-terminal extension
did not affect substrate binding, indicating substrate-chaperone interactions likely occurs in
SBD-β. However, removing SBD-α and the C-terminal extension in the SBD9, SBD10, and
SBD11 constructs did not disrupt substrate binding, showing the initial SBD-β substitutions
were not disruptive. I also attempted to create a Hsc70CbΔSBD-β ΔC-term construct but I was
unable to purify a stable protein for the aggregation assay (data not shown). Overall, it
appears removing the SBD-α or C-terminal extension do not affect Hsc70Cb substrate
binding, indicating the SBD-β and either SBD-α or the C-terminal extension contain a
substrate binding region.
The totality of these data indicate Hsc70Cb may contain two distinct yet functionally
redundant substrate binding sites, as removal of the SBD-β and the C-terminal extension
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alone or in combination with SBD-α does not disrupt substrate binding activity. No literature
to date has indicated a dual substrate binding mechanism is present in Hsp70 or Hsp110
chaperones.

A preliminary paper using DnaK as a model for systematic mutations of

mammalian Hsp110 to elucidate functional similarities and differences shows SBD-β as the
primary substrate binding site (74).

Using recombinant Hsp110 from Cricetulus griseus

(Chinese hamster) a combination of deletions and truncations were made in the NBD, SBDβ, extended loop, and/or α-helical lid that showed removal of the SBD-β, but not the SBD-α
or carboxyl-terminus, primarily disrupted substrate binding (74). Specifically, the absence of
SBD-β greatly reduced the solubility and foldability of chemically denatured luciferase.
Interestingly, constructs in which SBD-β, including the extended loop, were attached to a
truncated SBD-α domain showed reduced substrate binding compared to full-length Hsp110
or SBD-β attached to the entire carboxyl-terminal region. This result indicates the region
carboxyl-terminal to SBD-β mediates substrate binding in some capacity. A more recent study
of ER-localized Hsp110, Grp170, shows removal of the carboxyl-terminus, which includes the
α-helical lid (SBD-α) and the region corresponding to the C-terminal extension, reduces
binding to three separate substrates compared to full-length Grp170 (258).

This data

suggests dual binding mechanism for Grp170. However, the authors interpreted these results
as the carboxyl-terminus of Grp170 influencing SBD-β activity rather than independently
modulating substrate binding.
In summary, it appears the SBD-β subdomain and another region carboxy-terminal to
it mediate substrate binding in Hsc70Cb. No published literature to date has indicated
Hsc70Cb or any other Hsp110 can interact with unfolded substrates at two separate sites.
The results contained within this chapter raise the question of whether Hsc70Cb possesses a
dual substrate binding mechanism that has yet to be uncovered. And, if such a mechanism
exists, is it unique to fly Hsp110, or is it a feature present in other Hsp110 homologs? In the
following chapter I will further my investigation of Hsc70Cb substrate binding activity through
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the creation of several Hsc70Cb domain fusion constructs. These fusions will allow me to
localize a potential secondary substrate binding site contained with Hsc70Cb. Furthermore, I
assess whether this presumed dual substrate binding mechanism is unique to Hsc70Cb or
present in other Hsp110s from yeast to humans. I will also assess to what extent the
independent chaperoning activity of Hsc70Cb can suppress the oligomerization of
neurodegenerative disease-associated peptides in vitro.
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Chapter IV:
Hsc70Cb contains a novel secondary substrate binding site
carboxyl-terminal to SBD-β

NOTE: Portions of this chapter were derived from work previously published in The
Journal of Biological Chemistry (JBC). Yakubu, U. M., and Morano, K. A. (2021)
Suppression of aggregate and amyloid formation by a novel intrinsically disordered
region in metazoan Hsp110 chaperones. J. Biol. Chem. 296, 100567 (274). JBC does
not

require

permission

to

use

published

materials

in

https://www.elsevier.com/about/policies/copyright/permissions.
.
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one’s

dissertation:

Introduction

In the previous chapter I detailed my initial attempts at disrupting the substrate binding
activity of Hsc70Cb. My inability to do this with point mutations and select whole domain
deletion mutants led me to further investigate the mechanism by which Hsc70Cb binds and
prevents aggregation of unfolded polypeptides. Given the previously presented data, I posit
there are multiple substrate binding sites in Hsc70Cb.

Previous literature on Hsp110

chaperones has not suggested the presence of a secondary binding site.

Early work

describing deletions to the Chinese hamster Hsp110 revealed the putative substrate binding
domain, SBD-β, to prevent aggregation of denatured firefly luciferase (74). Likewise, work
detailing the substrate binding activity of yeast Hsp110, Sse1, confirm the SBD-β subdomain
as the primary substrate binding site in this chaperone (47, 72, 249, 259). These studies
suggest canonical Hsp110s possess a single substrate binding region; however, it is possible
Hsc70Cb mediates this activity via a novel mechanism.
The ability of molecular chaperones to interact with substrates at multiple binding sites
is not a unique occurrence. It appears Hsp70 chaperones possess the ability to bind
substrates at multiple sites, primarily SBD-β and another carboxy-terminal site (260, 261).
One study showed GGAP and GGAP-like tetrapeptide repeat motif at the far carboxy-terminal
of yeast Hsp70, Ssa1, mediates transient interacts with folding substrates and Ydj1 (Hsp40).
Specifically, this region enhances Ssa1 binding to the yeast prion protein Ure2, thus inhibiting
Ure2 fibril formation (261). Furthermore, the authors of this study found there were in vivo
consequences for the removal of the GGAP-motif. Particularly, loss of this motif disrupts the
ability of yeast cells to recover from heat and cell wall stress (261). In another paper following
my research article in The Journal of Biological Chemistry, it was shown that a non-canonical
binding site, generally localized between SBD-α and the carboxy-terminal EEVD-motif in
DnaK can bind and suppress α-synuclein aggregation in vitro (260). In both studies the
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mechanism by which Hsp70 chaperones mediate non-canonical substrate binding occurs in
a passive, ATP-independent manner, and appears to be separate from the protein interactions
required for Hsp70 foldase activities.
In addition to localizing a potential secondary substrate binding site, I want to evaluate
whether the anti-aggregation effects of Hsc70Cb can also prevent oligomerization of diseaseassociated polypeptides. Numerous models of human neurodegenerative disease reveal loss
of Hsp110 is implicated in disease onset and advancement (113, 116, 118, 206, 220, 221).
Strikingly, overexpression of the respective Hsp110 chaperones was shown to ameliorate
disease-linked aggregation and symptoms in these models (113, 116, 119, 120, 220, 221). In
vitro studies mirror these findings, showing Hsp110 activity is crucial of amyloid disassembly
in the mammalian disaggregase system (113, 116, 117). While the totality of these studies
presents a cogent argument for the importance of Hsp110 chaperoning in disease, these
findings do not differentiate between Hsp110 activities as a co-chaperone for Hsp70 and
independent holdase studies. In this study I try to elucidate what role Hsc70Cb substrate
binding has on preventing disease-associated protein aggregation using the peptides amyloid
β 42 (Aβ1-42 or Aβ42) and α-synuclein.
Neurodegenerative diseases are characterized by the progressive deterioration and
eventual death of tissues in the brain, spinal cord, motor neurons or any other neuronal tissues
of the central nervous system (10). There is a diverse profile for degenerative neuropathies,
the most common being age-related dementias perpetuated by the misfolding and
aggregation of select proteins as seen in Alzheimer’s and Parkinson’s diseases. Purely
genetic neurodegenerative disorders which include Huntington’s disease and spinocerebellar
ataxias are rare in comparison. In these neuropathies a mutation in a protein-encoding gene
causes the protein to be more susceptible to misfolding. Transmissible spongiform
encephalopathies (TSE), or prion diseases, are exceedingly rare disorders caused by the
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templated fibrilization of prion proteins in the brain, these disorders can be sporadic, familial,
or acquired from exposure to infected tissues, hosts, or foods (10).
1 in 10 people over the age of 65 develop Alzheimer’s disease, making it most
prevalent neurodegenerative disorder worldwide (262). Disease progression is mediated by
the amyloidogenic cleavage of the amyloid precursor protein (APP) by β- and !-secretases
into short peptide species called amyloid β (Aβ) (Figure 4-1) (263). APP is a type I
transmembrane protein and member of the APP-like protein gene family, with three known
isoforms: APP695, APP751, and APP770. The APP695 isoform is highly expressed on neuronal
cells, particularly in neuronal synapses (264, 265). While its exact function is not known, APP
has been shown to modulate synapse formation and function, and act a signal transducer in
neuronal cells to promote adhesion and cell survival (264, 266). Further processing of Aβ into
the 40 (Aβ1-40) and 42 (Aβ1-42) amino acid species creates Aβ monomers that readily assemble
into extracellular aggregates, oligomers, and eventually intractable amyloid fibrils. Aβ
fibrilization is thought to induce disease symptoms by impairing synaptic firing leading to
memory loss and dementia in patients (264).
Parkinson’s disease is the second most common neurodegenerative disorder with a
prevalence of 2-3% in people age 65 and older (267). The disorder is characterized by the
general loss of dopaminergic neurons in the substantia nigra, a region of the brain largely
responsible for movement (189, 268, 269). Loss of the substantia nigra leads to dementia and
deterioration of neuromuscular functions causing dysfunctions in motor movements, muscle
rigidity, and the development of a steady and permanent tremor. Degeneration of the
substantia nigra is mediated by the aggregation of α-synuclein into Lewy bodies, a phenotype
seen in all Parkinson’s disease patients. α-synuclein is small 140-residue peptide of
ambiguous function predominately expressed in the brain. It exists in either a lipid membranebound or soluble cytosolic state, and its structure largely depends on where it is localized. The
amino-terminus of α-synuclein contains a hepta-repeat of a conserved 11-residue motif that
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folds into an α-helical structure when embedded in a lipid membrane (Figure 4-1). However,
monomeric α-synuclein remains in an unfolded, yet soluble, state in the cytosol (268, 269).
Mutations in the amino-terminal region of α-synuclein have been shown to cause familial, early
onset Parkinson’s disease.
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Figure 4-1: Folding conformations for amyloid β and α-synuclein
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Figure 4-1: Folding conformations for amyloid β and α-synuclein. A. amyloid
precursor protein (APP) is cleaved by β- and !-secretases to release monomeric amyloid
β (Aβ). Aβ monomers misfold and forms amorphous tangles which become intractable
amyloid fibrils present in Alzheimer’s brains. B. α-synuclein exists in one of two native
states: lipid-membrane-bound multimers or cytosolic unfolded (but soluble) monomers.
Unfolded monomers can misfold and form protofibrils and amyloid fibrils that become
incorporated into Lewy bodies characteristic of Parkinson’s disease brains.
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The number one risk factor for the development of neurodegenerative disorders is
aging. In nearly all degenerative neuropathies, disease and associated symptoms do not
occur until the patient has reached middle age or older (262, 270). The onset of disease often
coincides with age-related declines in the proteostatic network (175, 200, 204, 205, 271). With
age protective cellular networks become overburdened by the accumulation of stressors
making it more difficult for proteome machinery to rapidly refold or degrade aberrant proteins.
Post-mitotic cells like neurons are especially susceptible to amassing misfolded proteins and
toxic aggregates that go uncleared. Neuronal cells do not have the advantage of cell division
to act as a dilution mechanism for protein aggregates. Instead of splitting or allowing one
daughter cell to inherit the aggregate load post-mitotic cells continue to accumulate misfolded
proteins until they reach a critical mass and begin to negatively affect cellular function. One
theory as to why declines in proteostasis occur with age is the lack of selective pressure on
the proteostatic network once an organism is past viable reproductive age (272). To date,
there are no curative treatments for neurodegenerative diseases and understanding the
biological processes behind these disorders will help elucidate pathways that can be
manipulated for treatments.
One way to combat neurodegenerative diseases is to create therapeutics that
increase the presence of molecular chaperones in the cell. Numerous animal models of
neurodegeneration show upregulating the chaperone network leads to a reduction in the
misfolding and oligomerization of disease-associated proteins (113, 199, 221, 273).
Specifically, the upregulation of Hsp110 chaperones has been shown to alleviate, postpone
onset, and even reverse disease associated aggregation and neurological symptoms (116,
118–120, 206, 220, 221). The absence of a Hsp104 homolog in mammalian species leaves
the core Hsp70-40-110 machinery as the only means for disaggregation in the cell. In Hsp70mediated disaggregation Hsp110 is the rate limiting chaperone, as its levels in mammalian
cells drives the folding activity of Hsp70, albeit slowly (113, 117, 222). Furthermore, Hsp110
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has been shown to act independently of the Hsp70 folding cycle to prevent protein aggregation
(72–74, 274). Understanding the role of Hsp110 as an indirect – through Hsp70 – and direct
modulator of aggregation in human disease could reveal a previously unknown therapeutic
target.
In this chapter I detail the creation of several Hsc70Cb fusion constructs that I will use
to localize a potential substrate binding site carboxy-terminal to SBD-β. For this endeavor, I
employed the use of in silico prediction algorithms to identify a previously overlooked region
contained within the far carboxy-terminus of Hsc70Cb. The PSIPRED workbench, which
includes PSIPRED (secondary structure prediction) and DISOPRED (disordered region
prediction) algorithms, was used to informed the design of the Hsc70Cb fusion constructs
used in this study (275).

Resultant fusion constructs were screened in vitro using the

previously established aggregation light scatter assay (251). Additionally, thioflavin T binding
assays and transmission electron microscopy were used to characterize the ability of
Hsc70Cb and human Hsp110, Hsp105α, fusion constructs to suppress oligomerization of
amyloid β 42 (Aβ1-42) and α-synuclein peptides in vitro.
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Results

Deletion of the putative substrate binding site at the SBD-β subdomain did not have
any effect on Hsc70Cb substrate binding activity. This result caused me to search for other
sites of interest within the chaperone. The crystal structure of metazoan Hsp110s has yet to
be fully elucidated, however the degree of conservation between Hsp110s in all kingdoms and
the use of prediction algorithms allows for reliable predictions of protein structure and
constitution. To identify potential sites of interest I used PSIPRED Workbench, a protein
prediction server that coalesces several prediction methods to allow for comprehensive
forecasting of protein structure, function, and conservation based on amino acid sequence
similarities when compared to proteins of known structure and function (275). For my analysis
of Hsc70Cb I primarily relied upon structural predictions provide by PSIPRED 4.0 and
DISOPRED3. PSIPRED 4.0 predicts protein secondary structure, allowing me to delineate
predicted α-helices from β-sheets, loops or coils within Hsc70Cb. This algorithm was used to
inform the boundaries for Hsc70Cb fusion constructs. DISOPRED3 is a machine-learning
based algorithm used to detect potential sites of disorder within proteins by comparing
sequence features to known natively disordered regions allowing for high confidence
predictions of intrinsic disorder (276, 277).
Using DISOPRED3, I was able to pinpoint two sites of potential disorder within
Hsc70Cb; the first localized to the extended loop between SBD-β and SBD-α and the second
mapped to amino acids 751-804 in the far C-terminal extension of Hsc70Cb corresponding to
amino acids 666-804 (Figure 4-2). The information provided by the disordered prediction lead
me to create the NBD-C-term fusion construct. This construct takes the non-chaperoning NBD
of Hsc70Cb and fuses it to the C-terminal extension. By screening this construct with the light
scatter aggregation assay I was able to show the C-terminal extension confers a substrate
binding capacity to NBD (Figure 4-3). This construct corroborates findings from the previous
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chapter - deletion of SBD-β does not disrupt substrate binding because the far carboxylterminus of Hsc70Cb contains a potent substrate binding capacity.
The presence of a secondary binding capacity has not been demonstrated in any
Hsp110 to date. For this reason, I wanted to know whether this activity was unique to
Drosophila Hsp110 or conserved in other species. I used the UniProt protein database to
obtain verified amino acid sequences for yeast, fly, and human Hsp110s, and used Clustal
Omega to align the sequences for analysis (278, 279). Upon investigation, it appears the Cterminal extension is absent in yeast Sse1 but present in Hsc70Cb and the human Hsp110s,
Apg-1 and Hsp105α (Figure 4-4). The presence of the far C-terminal extension in human
homologs of Hsp110 was an intriguing discovery, especially considering previous
investigation of Hsp110 activity did not include this region for analysis (47, 73, 74). The
presence of this region in human Hsp110s led me to question whether the human C-terminal
extensions were sufficient to prevent protein aggregation. To investigate, I created chimeric
NBD-C-term constructs, fusing fly NBD to the C-terminal extensions of Apg-1 and Hsp105α.
Following successful expression and purification, these constructs were screened using the
light scatter aggregation assay. Similar to fly NBD-C-term, both Apg-1 and Hsp105α chimeric
constructs potently suppressed the aggregation of denatured citrate synthase (Figure 4-5).
While Apg-2 is a mammalian Hsp110 distinct from both Hsp105α and Apg-1, the high degree
of BLAST calculated sequence similarity (63%) and positive substitutions (78%) between Apg1 and Apg-2 makes me conclude the Apg-2 C-terminal extension is likely functionally
comparable to that of Apg-1 (Figure 4-6). However, this hypothesis remains to be tested.
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Figure 4-2: DisoPred Plot for Hsc70Cb
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Figure 4-2: DisoPred Plot for Hsc70Cb. Disorder prediction of Drosophila melanogaster
(fruit fly) Hsc70Cb using DISOPRED3 from the PSIPRED Workbench. The peak from
approximately 500 to 560 correspond to the extended loop between the SBD-β and SBDα subdomains. The peaks from 750 to 804 represents a predicted intrinsically disordered
region contained within in the far carboxy-terminal extension. Peaks above the dotted line
(> 0.5 confidence score) indicate regions of predicted disorder.
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Figure 4-3: C-terminal extension of Hsc70Cb prevents protein aggregation
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Figure 4-3: C-terminal extension of Hsc70Cb prevents protein aggregation. A.
Schematic of Hsc70Cb domain architecture and indicated deletions or fusions. B. 200 nM
denatured CS was incubated alone (no chaperone) or with 400 nM of respective
chaperone: Hsc70Cb, NBD, NBD-C-term. Bolded lines are the average of three replicates
for each condition while the shaded region represents standard error of the mean (SEM).
C. End point measurements of each condition were taken from (B) and divided by the no
chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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Figure 4-4: Clustal Omega alignment of carboxyl-terminus of yeast, fly, and human
Hsp110s
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Figure 4-4: Clustal Omega alignment of carboxyl-terminus of yeast, fly, and human
Hsp110s. Clustal Omega sequence alignment of the carboxyl-termini of Sse1 (budding
yeast), Hsc70Cb (fruit fly) and Hsp105α (human) Hsp110 homologs. KEY: (*) – single fully
conserved residue (:) - conservation between residues of strongly similar properties (.) –
conservation between residues of weakly similar properties.
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Figure 4-5: C-terminal extension substrate binding is conserved between fly and
human Hsp110s
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Figure 4-5: C-terminal extension substrate binding is conserved between fly and human
Hsp110s. A. Schematic of Hsc70Cb domain architecture and indicated deletions or fusions.
B. 200 nM denatured CS was incubated alone (no chaperone) or with 400 nM of respective
chaperone: Hsc70Cb, NBD-C-termHsc70Cb, NBD-C-termApg-1, NBD-C-termHsp105α. Bolded lines
are the average of three replicates for each condition while the shaded region represents
standard error of the mean (SEM). C. End point measurements of each condition were taken
from (B) and divided by the no chaperone measurement within the respective replicate and
converted to relative percentage. Group differences were analyzed using Welch’s t-test. *,
p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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Figure 4-6: Human Apg-1 and Apg-2 have similar disorder predictions and a highly
conserved C-terminal extension
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Figure 4-6: Human Apg-1 and Apg-2 have similar disorder predictions and a highly
conserved C-terminal extension. A. Disorder prediction for Apg-1 using DISOPRED3.
Peaks above the dotted line (> 0.5 confidence score) indicate regions of predicted disorder.
B. Disordered prediction for Apg-2 C. Clustal Omega alignment of Apg-1 and Apg-2
carboxyl-terminal extensions. KEY: (*) – single fully conserved residue (:) - conservation
between residues of strongly similar properties (.) – conservation between residues of
weakly similar properties.
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To further elucidate which residues mediate substrate binding activity in the C-terminal
extension I used PSIPRED to assess the predicted structure of this region. PSIPRED predicts
the C-terminal extension to contain three α-helices followed by an intrinsically disordered
region (IDR). The IDR was of particular interest to me because disordered regions have been
found to assume order when interacting with other proteins or polypeptides (280–282).
Additionally, the chaperoning activity of sHSPs has been shown to be mediated, in part, by
conserved intrinsically disordered regions, suggesting that putative Hsp110 IDRs may be
responsible for the observed substrate binding capacity (243, 281, 283–285). To test this
hypothesis, I created two additional constructs using Hsc70Cb: NBD-IDR and NBD-CtermΔIDR. NBD-IDR was made by using PCR to amplify the Hsc70Cb IDR and appending it to
NBD. Upon purification NBD-IDR was screened in vitro and I was able to show the predicted
IDR, corresponding to amino acids 751-804, is sufficient to prevent aggregation of denatured
citrate synthase (Figure 4-7).
As a confirmatory approach the NBD-C-termΔIDR construct was created. Using PCR, I
removed the predicted IDR and two α-helices (H2 and H3) from NBD-C-term, leaving only the
first predicted α-helix (H1). This construct was stably expressed and purified, then screened
for binding activity using the citrate synthase aggregation assay. Removing the predicted IDR
results in loss of substrate binding activity when compared to the full-length NBD-C-term
construct (Figure 4-8). It is worth noting that NBD-C-termΔIDR appears to be co-aggregating
with denatured citrate synthase causing an absorbance reading higher than that of the no
chaperone control. One explanation is that NBD-C-termΔIDR can bind unfolded substrates, but
this binding is insufficient to prevent aggregation. Nonetheless, the data from this assay and
the NBD-IDR and NBD-C-term assays together show the IDR is needed for carboxyl-terminal
substrate binding activity.
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Figure 4-7: C-terminal IDR of Hsc70Cb prevents aggregation when fused to NBD
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Figure 4-7: C-terminal IDR of Hsc70Cb prevents aggregation when fused to NBD. A.
Schematic of Hsc70Cb domain architecture and indicated deletions or fusions. B. 200 nM
denatured CS was incubated alone (no chaperone) or with 400 nM of respective
chaperone: Hsc70Cb, NBD, NBD-IDR. Bolded lines are the average of three replicates for
each condition while the shaded region represents standard error of the mean (SEM). C.
End point measurements of each condition were taken from (B) and divided by the no
chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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Figure 4-8: Removing predicted IDR from NBD-C-term disrupts substrate binding
activity
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Figure 4-8: Removing predicted IDR from NBD-C-term disrupts substrate binding
activity. A. Schematic of Hsc70Cb domain architecture and indicated deletions or fusions.
Swirls represent α-helices and dotted line represented IDR. B. 200 nM denatured CS was
incubated alone (no chaperone) or with 400 nM of respective chaperone: Hsc70Cb, NBDC-term, NBD-C-termΔIDR. Bolded lines are the average of three replicates for each condition
while the shaded region represents standard error of the mean (SEM). C. End point
measurements of each condition were taken from (B) and divided by the no chaperone
measurement within the respective replicate and converted to relative percentage. Group
differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****,
p=0.00005.

114

Mirroring the secondary structure prediction for Hsc70Cb, the PSIPRED prediction for
Hsp105α indicate this chaperone also contains three predicted α-helices followed by an IDR
in the far carboxyl-terminus, amino acids 718-858. (Figure 4-9). To confirm the substrate
binding capacity of the Hsp105α C-terminal extension I created a chimeric fly-Hsp105α NBDIDR construct. Using this construct, I was able to show the predicted IDR, amino acids 803858, in the Hsp105α C-terminal extension mediates substrate binding, acting in a similar
capacity to the Hsc70Cb IDR (Figure 4-10). The PSIPRED results of Apg-1/2 chaperones also
predict the C-terminal extension to contain three α-helices and an IDR. Due to the familial and
predicted structural similarities between Apg-1/2 and Hsp105α I predict Apg-1/2 chaperones
both mediate C-terminal substrate binding in their respective IDRs (Figure 4-6). Furthermore,
the chimeric NBD-C-termApg-1 was able to suppress substrate aggregation, indicating the Cterminal extension, and likely the IDR contained within it, mediates this activity.
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Figure 4-9: DisoPred Plot for human Hsp105α
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Figure 4-9: DisoPred Plot for human Hsp105α. Disorder prediction of Hsp105α using
DISOPRED3. Hsp105α carboxy-terminal extension is comprised of amino acids 718-858.
The Hsp105α IDR is located from amino acids 803-858. Peaks above the dotted line (> 0.5
confidence score) indicate regions of predicted disorder.
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Figure 4-10: Fly and human IDRs prevent citrate synthase aggregation
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Figure 4-10: Fly and human IDRs prevent citrate synthase aggregation. A. Schematic
of Hsc70Cb domain architecture and indicated deletions or fusions. B. 200 nM denatured
CS was incubated alone (no chaperone) or with 400 nM of respective chaperone:
Hsc70Cb, NBD-C-termHsp105α, NBD-IDRHsc70Cb, NBD-IDRHsp105α. Bolded lines are the
average of three replicates for each condition while the shaded region represents standard
error of the mean (SEM). C. End point measurements of each condition were taken from
(B) and divided by the no chaperone measurement within the respective replicate and
converted to relative percentage. Group differences were analyzed using Welch’s t-test. *,
p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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The C-terminal extensions, while absent in yeast, are conserved in metazoan species;
particularly, this region is contained in all three human Hsp110 homologs. The conservation
of the C-terminal extension in human and fly Hsp110s led me to conclude there may be an
evolutionary advantage conferred to species that possess this region. Specifically, I propose
Hsp110 IDRs may mediate biologically relevant protein aggregation in some capacity. To test
this concept, I evaluated the ability of fly and human C-terminal IDRs to block aggregation of
peptides associated with human neurodegenerative diseases. I selected peptides implicated
in Alzheimer’s and Parkinson’s diseases for this assessment because they have been shown
to oligomerize both in vitro and in vivo, making these peptides a biologically relevant and
straightforward model of disease-associated aggregation in vitro.
I utilized an in vitro thioflavin T binding assay, in which the small molecule thioflavin T
(ThT) binds structured β-sheets present in amyloid fibrils and emits a detectable fluorescence
signal (286, 287). I was interested to test the peptide amyloid β 42 (Aβ1-42), one of several
short cleavage products of APP that comprise a significant amount of protein found in
Alzheimer’s associated amyloid fibrils (263, 264, 288). Aβ1-42 was selected over Aβ1-40 because
its aggregation occurs more rapidly, with detectable amyloids forming over the course of hours
instead of days (289, 290). Monomeric Aβ1-42 was added to the ThT binding reaction and
amyloid formation was assessed by tracking increases in fluorescence signal over the course
of 16 hr. Using this assay, I showed 2 μM Aβ1-42 monomers form detectable amyloid fibrils in
the absence of chaperone (Figure 4-11). To test whether NBD-IDRs prevent Aβ1-42
aggregation I added 4 μM of either NBD, NBD-IDRHsc70Cb, or NBD-IDRHsp105α to 2 μM
monomeric Aβ1-42 and monitored changes in fluorescence signal over time. The addition of
either NBD-IDRHsc70Cb or NBD-IDRHsp105α to the reaction suppressed Aβ1-42 amyloid formation.
Predictably, non-chaperoning NBD did not prevent Aβ1-42 amyloid formation, as addition of
NBD had the same fluorescence profile as Aβ1-42 incubated alone (Figure 4-12).
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Figure 4-11: Thioflavin T binds Aβ1-42 fibrils and gives off a detectable fluorescence
signal

A.
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Figure 4-11: Thioflavin T binds Aβ1-42 fibrils and gives off a detectable fluorescence
signal. A. Schematic of thioflavin T (ThT) mechanism of action. Monomeric Aβ1-42 is
incubated at 37 ℃ with thioflavin T. Over time misfolding Aβ1-42 forms amyloid fibrils to
which thioflavin T binds and gives off a detectable fluorescence signal B. 2 μM Aβ1-42 is
incubated with 5 μM thioflavin T in buffer and fluorescence measurements are taken as
described in Materials and Methods.
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Figure 4-12: NBD-IDRs prevent oligomerization of Alzheimer’s disease peptide Aβ42

A.

80000 Aβ42
60000

NBD-only
NBD-IDRHsc70Cb
NBD-IDRHsp105α

40000
20000

4

8

12

Time (hr)

C.

ns

120

✱✱

100
80
60
40
20

123

D
B
N

5α

H

sp

70

B

D

-ID

R

H

sc

A
R
-ID
N

D

10

C

b

β4
2

0

B

0

N

0

Percent Oligomerization (%)

Relative Fluorescence Units

B.

16

Figure 4-12: NBD-IDRs prevent oligomerization of Alzheimer’s disease peptide Aβ42.
A. Schematic of Hsc70Cb domain architecture and indicated deletions or fusions. B. 2 μM
of Aβ1-42 was incubated alone or with 4 μM of respective chaperone: NBD, NBD-IDRHsc70Cb,
NBD-IDRHsp105α in the presence of thioflavin T. Fluorescence measurements were taken as
described in Materials and Methods. Bolded lines are the average of three replicates for
each condition while the shaded region represents standard error of the mean (SEM). C.
End point measurements of each condition were taken from (B) and divided by the Aβ42
measurement within the respective replicate and converted to relative percentage. Group
differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****,
p=0.00005.
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α-synuclein was also a peptide of interest, as it is present in Lewy bodies and other
amyloid species found in the brains of Parkinson’s disease patients (193, 268, 269). In
contrast to Aβ1-42, α-synuclein requires a pre-formed fibril to act as a seeding element in vitro
and has a longer aggregation timeframe. For this assay, seeded α-synuclein monomers were
added to the ThT binding reaction buffer and allowed to aggregate over 24 hr. I was able to
reproduce the results of the Aβ1-42 assays with α-synuclein and show both NBD-IDRs, but not
NBD, suppressed α-synuclein fibril formation (Figure 4-13). Interestingly, when comparing αsynuclein alone to the chaperone containing conditions there is a noticeable early spike,
where it appears the presence of these chaperones is causing more rapid aggregation.
However, by the 24 hr time point the α-synuclein and NBD conditions have comparable
endpoint aggregation while the endpoints for the NBD-IDR containing reactions show
suppression of α-synuclein oligomerization relatively early in the assay.
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Figure 4-13: NBD-IDRs prevent α-synuclein oligomerization in vitro
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Figure 4-13: NBD-IDRs prevent α-synuclein oligomerization in vitro. A. 2 μM of αsynuclein monomers (α-Syn M) and 1 μM pre-formed fibrils (α-Syn PFF) where incubated
together (α-syn M+PFF) or with 4 μM of respective chaperone: NBD, NBD-IDRHsc70Cb, NBDIDRHsp105α for 24 hr and thioflavin T fluorescence detected as described in Materials and
Methods. Bolded lines are the average of three replicates for each condition while the
shaded region represents standard error of the mean (SEM). B. End point measurements
of each condition were taken from (A) and divided by the α-syn M+PFF measurement
within the respective replicate and converted to relative percentage. Group differences
were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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To further evaluate the binding capacity of NBD-IDR and substantiate the finding from
the thioflavin binding assays transmission electron microscopy (TEM) was used to directly
quantify amyloidogenesis. With the help of Drs. Bo Hu, Pratick Khara, and Kohei Kishida in
the Department of Microbiology and Molecular Genetics, McGovern Medical School, I was
able to obtain endpoint images of each condition in the Aβ1-42 assay. Validating what was
shown in the kinetic assays, TEM revealed that the NBD-IDR constructs indeed reduced
amyloid fibril formation. Specifically, addition of NBD-IDR chaperones to Aβ1-42 dramatically
reduced the size and length of amyloid fibrils. In contrast Aβ1-42 alone or in the presence of
NBD formed extensive, long, and tangled amyloid fibrils (Figure 4-14). An interesting note is
the formation of globular particles in the NBD-IDRHsp105α condition. These particles were also
observed when NBD-IDRHsp105α was incubated in the thioflavin T binding buffer without
substrate (Figure 4-15), indicating this is a property of NBD-IDRHsp105α that is independent of
its interactions with Aβ1-42. Fly NBD-IDR does not form these particles, and it appears this
structure is not required for IDR-mediated chaperoning activities.
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Figure 4-14: Transmission electron microscopy images confirm NBD-IDR constructs
block Aβ1-42 fibrilization
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Figure 4-14: Transmission electron microscopy images confirm NBD-IDR constructs
block Aβ1-42 fibrilization. Endpoint samples from the Aβ1-42 thioflavin T binding assay were
recovered, negative stained, and imaged via transmission electron microscopy, with or
without additional chaperones as indicated in Materials and Methods. Scale bar = 200 nm.
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Figure 4-15: NBD-IDRHsp105α forms globular particles in vitro
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Figure 4-15: NBD-IDRHsp105α forms globular particles in vitro. A. 4 μM NBD-IDRHsp105α
was incubated without substrate as described for Fig. 4-12. B. Endpoint samples from the
thioflavin T binding assay (A) were recovered, negative stained, and imaged via
transmission electron microscopy. Particle size was measured (n=10) using ImageJ on the
zoomed inset image. Scale bar= 200 nm. B. NBD-IDRHsp105α is not self-oligomerizing in
thioflavin T binding assay.
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The potency with which the NBD-IDR constructs suppressed fibril formation led me to
question the quantity of chaperone required to inhibit Aβ1-42 fibril formation. I wanted to know
the limits of NBD-IDR chaperoning activity and the minimum concentration of NBD-IDR
required to suppress amyloid formation. To this end I conducted a dose-dependent ThT
binding assay where 2 μM monomeric Aβ1-42 was incubated alone or with .25x, .5x, 1x, or
2x concentration of NBD-IDRHsp105α. For the concentrations and ratios selected, NBDIDRHsp105α was sufficient to suppress Aβ1-42 fibrilization, even in relatively small quantities. It
appears halving or even quartering the amount of chaperone in the reaction does not change
Aβ1-42 fibrilization kinetics (Figure 4-16). This is a distinct contrast from the light scatter assay
results which show full-length Hsc70Cb prevents substrate aggregation in a dose-dependent
manner using the same substrate-to-chaperone ratios (Figure 3-1). Further investigation is
needed to assess the stochiometric capacity of NBD-IDR to prevent amyloid formation, as it
appears a relatively small amount of IDR is needed for amyloid suppression. Further
characterization of NBD-IDRHsp105α showed adding the chaperone to actively forming Aβ1-42
oligomers halts the growth of fibrils (Figure 4-17). However, adding NBD-IDRHsp105α to stable
Aβ1-42 fibrils does not resolve the aggregates (reverse aggregation) (Figure 4-17). These
results correspond with the previously established functions of mammalian Hsp110. In the
absence of Hsp70 and Hsp40, Hsp110 does not have the ability to act as an independent
disaggregase, but is competent to prevent aggregation of unfolded substrates (113, 117).
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Figure 4-16: NBD-IDRHsp105α prevents Aβ1-42 oligomerization at sub stochiometric
levels

40000

Aβ42
4 µM
2 µM
1 µM
.5 µM

30000
20000
10000
0

4

8
Time (hr)

B.

✱✱✱
✱✱

100

80

60

40

20

134

μM

μM

μM

.5

1

4

2

μM

A

β4

2
μM

0

2

0

Percent Oligomerization (%)

Relative Fluorescence Units

A.

12

16

Figure 4-16: NBD-IDRHsp105α prevents Aβ1-42 oligomerization at sub stochiometric levels.
A. 2 μM of Aβ42 was incubated alone or with NBD-IDRHsp105α at .25x, .5x, 1x, or 2x
concentration. Bolded lines are the average of three replicates for each condition while the
shaded region represents standard error of the mean (SEM). B. End point measurements of
each condition were taken and divided by the no chaperone measurement within the
respective replicate and converted to relative percentage. Group differences were analyzed
using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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Figure 4-17: NBD-IDRHsp105α blocks the formation of growing fibrils but not preformed fibrils
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Figure 4-17: NBD-IDRHsp105α blocks the formation of growing fibrils but not preformed fibrils. A. 2 μM of Aβ1-42 was incubated in the presence of thioflavin T. At 4 hr 4
μM NBD-IDRHsp105α was added to the reaction; measurements were taken for an additional
20 hr. B. 2 μM of Aβ1-42 was incubated in the presence of thioflavin T. At 20 hr 4 μM NBDIDRHsp105α was added to the reaction; measurements were taken for an additional 6 hr. C.
End point measurements of each condition were taken from (B) and divided by the Aβ42
chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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The cumulative results of the light scatter and thioflavin T binding assays confirmed
the presence of a potent substrate binding site in the IDR region. However, for these assays
I used a fusion construct to assess the binding capacity of the IDR. Generally, I evaluated the
substrate binding activity of IDR by assessing its ability to confer holdase activity to the nonchaperoning NBD of Hsc70Cb. I wanted to isolate the IDR and evaluate its ability to suppress
aggregation as an independent entity. To do this, I utilized a synthetic IDR peptide generated
by Genewiz and tested its ability to prevent aggregation using the light scatter and thioflavin
T binding assays. The IDR peptide was predicted to be stable independent of Hsc70Cb and
has a predicted molecular weight of 5.45 kDa. In the light scatter assay incubating the IDR
peptide with denatured citrate synthase did not prevent citrate synthase aggregation (Figure
4-18). Following these results, I wanted to see if adding increasing amounts of IDR peptide to
the reaction would result in decreased citrate synthase aggregation. I conducted a light scatter
aggregation assay in which 200 nM denatured citrate synthase was incubated with 1, 25, 50,
or 100 μM of IDR peptide. These assays revealed adding up to 500x IDR peptide to the
aggregation reactions did not suppress citrate synthase aggregation (Figure 4-19).
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Figure 4-18: IDR peptide cannot prevent denatured citrate synthase aggregation
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Figure 4-18: IDR peptide cannot prevent denatured citrate synthase aggregation. A.
200 nM denatured CS was incubated alone (no chaperone) or with 400 nM Hsc70Cb, NBDIDR, or IDR peptide. B. Endpoint measurements of each condition were taken from (A)
and divided by the no chaperone measurement within the respective replicate and
converted to relative percentage. Group differences were analyzed using Welch’s t-test. *,
p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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Figure 4-19: IDR peptide cannot prevent aggregation independent of NBD
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Figure 4-19: IDR peptide cannot prevent aggregation independent of NBD. A. 200 nM
denatured CS was incubated alone (no chaperone) or with 1, 25, 50, or 100 μM IDR
peptide. B. Endpoint measurements of each condition were taken from (A)and divided by
the no chaperone measurement within the respective replicate and converted to relative
percentage. Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005;
***, p=0.0005; ****, p=0.00005.
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These results were somewhat contradictory to what I previously established, that the
IDR of Hsp110s is competent to prevent substrate aggregation. To further understand the
function of the Hsp110 IDR I decided to test whether IDR peptide co-incubated with NBD-IDR
enhanced the latter’s anti-aggregation activities. While the IDR peptide may not prevent
aggregation individually, I speculated the IDR peptide may have a synergistic effect when
NBD-IDR is present, increasing the anti-aggregation activity of NBD-IDR. I performed an
assay in which IDR peptide and NBD-IDR were both incubated with denatured citrate
synthase; the results showed IDR and NBD-IDR together have the same aggregation
suppression capacity as NBD-IDR alone (Figure 4-20). Likewise, the results of the thioflavin
T binding assay mirrored what was seen with citrate synthase light scatter, the IDR peptide
cannot suppress Aβ1-42 fibrilization (Figure 4-21). These data indicate the IDR peptide cannot
suppress substrate aggregation and oligomerization independent of NBD.
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Figure 4-20: IDR peptide does not synergize the anti-aggregation activity of NBD-IDR
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Figure 4-20: IDR peptide does not synergize the anti-aggregation activity of NBDIDR. A. 200 nM denatured CS was incubated alone (no chaperone) or with 400 nM NBDIDR or NBD-IDR + IDR peptide (400 nm). B. Endpoint measurements of each condition
were taken and divided by the no chaperone measurement within the respective replicate
and converted to relative percentage. Note: one outlier measurement in “NBD-IDR+IDR
peptide” condition was omitted from the statistical analysis, but remains in the kinetic data
(A). Group differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***,
p=0.0005; ****, p=0.00005.
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Figure 4-21: IDR peptide does not prevent Aβ1-42 oligomerization

50000

Aβ42
IDR peptide
Th T only
Buffer only

40000
30000
20000
10000

2

4

6

8

10

Time (hr)
B.

✱✱✱✱
✱
ns

100
80
60
40
20
0

r
Th on
l
ID
T y
R
on
pe
ly
pt
id Aβ
e
4
+ 2
A
β4
2

Percent Oligomerization (%)

0

uf
fe

0

B

Relative Fluorescence Units

A.

146

12

14

16

Figure 4-21: IDR peptide does not prevent Aβ1-42 oligomerization. A. 1 μM of Aβ1-42
was incubated alone or with 2 μM of IDR peptide (Hsc70Cb) in the presence of thioflavin
T. Bolded lines are the average of three replicates for each condition while the shaded
region represents standard error of the mean (SEM). B. End point measurements of each
condition were taken and divided by the Aβ42 measurement within the respective replicate
and converted to relative percentage. Note: one outlier measurement in the “IDR Peptide”
condition was omitted from the statistical analysis, but remains in the kinetic data. Group
differences were analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****,
p=0.00005.
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Discussion

Systematic analysis of Hsc70Cb substrate binding activity reveals the existence of a
novel substrate binding capacity in the far carboxyl-terminus (C-terminal extension or C-term)
of the fly Hsp110. Isolation and fusion of this region to the non-chaperoning NBD confers
substrate binding activity to the new construct NBD-C-term. This dual substrate binding
mechanism has not been shown to exist in any Hsp110 homolog to date, however the
existence of a secondary carboxy-terminal substrate binding region has recently been
uncovered in Hsp70 chaperones (291). While the light scatter aggregation assay is limited in
its resolution, it appears NBD-C-term constructs are better holdases than full-length Hsc70Cb
when using this method. It is unclear why this is the case, but one potential explanation is that
the native folding structure of Hsc70Cb may obscure the C-terminal extension, impeding its
ability to fully interact with substrates. However, appending the C-terminal extension to a
smaller domain may liberate this region, allowing for greater exposure of the binding site and
increased contacts with denatured substrates.

Importantly, the C-terminal extension is

capable of preventing the aggregation of a second model substrate, firefly luciferase,
confirming Hsc70Cb substrate binding is not specific to one class of unfolded proteins (Figure
4-22).
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Figure 4-22: C-terminal extension can prevent firefly luciferase aggregation in the
absence of SBD-β
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Figure 4-22: C-terminal extension can prevent firefly luciferase aggregation in the
absence of SBD-β. A. 200 nM denatured firefly luciferase was incubated alone (no
chaperone) or with 400 nM of respective chaperone/protein: Hsc70Cb, Hsc70CbΔSBDβ,
BSA. Bolded lines are the average of three replicates for each condition while the shaded
region represents standard error of the mean (SEM). B. End point measurements of each
condition were taken from (A.) and divided by the no chaperone measurement within the
respective replicate and converted to relative percentage. Group differences were
analyzed using Welch’s t-test. *, p=0.05; **, p=0.005; ***, p=0.0005; ****, p=0.00005.
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The substrate binding activity of fly and human Hsp110 C-terminal extensions is
mediated by a short intrinsically disordered region between 48 and 53 amino acids in length.
The IDRs, much like the C-terminal extensions, appear to be only loosely conserved in
metazoans. Both fly and human C-terminal extensions contain residues with similar
characteristics and charge, while not having a strict conservation pattern. Compared to their
respective full-length Hsp110s, C-terminal extensions, and especially the respective IDRs, are
highly charged with pI values ranging from 4.8-5.5 for C-terminal extensions and pI values
from 4.2-4.7 for IDRs. IDRs in both species show an enrichment of glycine, proline, and
otherwise negatively charged residues (Figure 4-23). Also, the presence of a C-terminal
extension is not unique to fly or human Hsp110s; of the metazoan species analyzed all appear
to contain a C-terminal extension region. Similar to the fly and human sequences, there
appears to be very loose conservation of this region in general. However, one point of
similarity among the metazoan sequences is the presence of a “XKPK” motif (Figure 4-24).
This motif exists as PKPK in human and non-human primates, bovine, and rodents, making it
the only fully conserved region in the mammalian IDRs analyzed. Further investigation is
needed to confirm the exact residues responsible for IDR-mediated substrate binding. Another
area of interest is evaluating and comparing the binding preferences of SBD-β and IDR.
Generally, Hsp110s preferentially bind substrates containing exposed aromatic residues
(249). However, the structural and sequence differences between SBD-β and the C-terminal
extension suggest these regions have different modes of chaperone-substrate interactions
despite being functionally redundant.
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Figure 4-23: Amino acid properties of fly and human Hsp110s
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Figure 4-23: Amino acid properties of fly and human Hsp110s. ExPasy – Protein
Parameters tool was used to calculate the percentage of amino acids and isoelectric points
of full-length, C-term, and IDRs of each respective Hsp110 chaperone (328). Residue
percentages highlighted in green represent enrichment compared to the respective fulllength chaperone; orange highlight represents a reduction.
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Figure 4-24: Multiple species alignment of metazoan Hsp110 carboxyl-terminus
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Figure 4-24: Multiple species alignment of metazoan Hsp110 carboxyl-terminus.
SnapGene software (Insightful Science; available at snapgene.com) and Clustal Omega
were used to align UniProt-verified sequences for Hsp110 homologs from the following
organisms: budding yeast (S. cerevisiae), fruit fly (D. melanogaster), human (H. sapiens),
orangutan (P. abelii), bovine (B. taurus), Chinese hamster (C. griseus), mouse (M.
musculus), and rat (R. norvegieus). Consensus sequence indicated in bold. Residues
included in the consensus sequence are present in more than 50% of aligned species.
Amino acids matching the consensus sequence are highlighted in pink. Bars indicate
percent conservation at a specific amino acid position. red: 75-100%; orange: 50-75%; blue
<50%.
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The results of the thioflavin T assays confirm Hsp110 chaperones can suppress the
aggregation and fibrilization of key peptides linked to human neurodegenerative diseases.
Unfortunately, full-length Hsp110s could not be used in these assays because thioflavin T
produces a fluorescence signal in the presence of full-length chaperone, falsely signifying
amyloid formation, despite the absence of aggregating protein. These results were also seen
when using the fly Hsp70 chaperone, Hsc70Ba, in the thioflavin T binding assay (Figure 425). I suspect thioflavin T is binding the β-sheets within in the SBD-β subdomain of Hsp110
and Hsp70 chaperones. This speculation is supported by data showing thioflavin T does not
produce a fluorescence signal when incubated with BSA, a protein comprised primarily of αhelices, or the unstructured IDR peptide (Figure 4-25).
The TEM images showed NBD-IDRHsp105α, but not NBD-IDRHsc70Cb, forms globular
particles in the thioflavin T binding assay. Initially I thought these structures were an artifact
of incubation with Aβ1-42, but NBD-IDRHsp105α forms these structures when incubated alone for
16 hr (Figure 4-15). The NBD-IDRHsp105α particles are similar in size and structure to those
formed by the sHSP αB-crystallin (292). Nevertheless, it does not appear the formation of
these structures is necessary for NBD-IDR chaperoning activity, as fly NBD-IDR does not form
these particles and has comparable chaperoning activity. Furthermore, it appears the IDR
needs an anchoring domain of some kind to suppress aggregation, as the IDR alone does not
display chaperoning activity. Perhaps the interactions between the IDR and substrates are
very transient, therefore a more rigid domain is necessary to hold the IDR in place long enough
to “trap” substrates. If this is the case, fusion of IDR to GFP or another non-chaperoning
protein should have the same aggregation suppressing function as the NBD-IDR constructs.
The presence of the carboxyl-terminal IDR has provided a new working model of the substrate
binding activities of Hsc70Cb. In this model substrate binding occurs independently at SBDβ or the carboxy-terminal IDR. Alternatively, substrate binding may also occur simultaneously
at both regions (Figure 4-26).
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The discovery of a novel chaperoning site in the C-terminal extension of metazoan
Hsp110s led me to question what role this region has in preventing protein aggregation in
vivo. The ability of Hsc70Cb and Hsp105α C-terminal IDRs to suppress Aβ1-42 and α-synuclein
oligomerization in vitro suggests this activity may exist in a disease context. Previous work
examining the biological functions of Hsp110 substrate binding in yeast paints an ambiguous
picture. Disrupting SBD-β does not cause any major cytotoxic stress in yeast cells (97).
Despite the results from this yeast study, examining the role of Hsp110s in a disease context
is still worthy of pursuit. The next step in the exploration of Hsc70Cb activities is to ascertain
whether it directly interacts with disease-associated peptides in an in vivo model. Experiments
evaluating substrate binding in vivo will provide insight regarding the therapeutic application
of Hsp110 chaperones in diseases of protein misfolding. This may be especially promising for
Huntington’s disease given the role Hsc70Cb plays as a strong inhibitor of huntingtin
aggregation in a fly model (220). To understand the function of Hsc70Cb substrate binding in
vivo I selected chaperone constructs, removing one or both binding regions, and
transgenically expressed them in fruit flies using the GAL4-UAS system. In the following
chapter I will discuss the in vivo consequences of disrupting Hsc70Cb substrate binding on fly
embryonic development and survival.
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Figure 4-25: Thioflavin T binds fly Hsp110 (Hsc70Cb) and Hsp70 (Hsc70Ba)
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Figure 4-25: Thioflavin T binds fly Hsp110 (Hsc70Cb) and Hsp70 (Hsc70Ba). A. 4 μM
Hsc70Cb was incubated with 5 μM thioflavin T in buffer at indicated concentrations for 16
hr.; fluorescence was measured as described in Materials and Methods. B. 4 μM Hsc70Ba
was incubated with 5 μM thioflavin T in buffer at indicated concentrations for 16hr;
fluorescence was measured as described in Materials and Methods C. 4 μM fly IDR peptide
or BSA was incubated with 5 μM thioflavin T in buffer and fluorescence was measured as
described in Materials and Methods.
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Figure 4-26: New model for Hsc70Cb substrate binding activity
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Figure 4-26: New model for Hsc70Cb substrate binding activity. Hsc70Cb (red) is a
nucleotide exchange factor for Hsp70 (blue). Hsp110 possess two substrate binding sites
located in the SBD-β subdomain and the carboxy-terminal extension. Both substrate
binding sites can suppress protein aggregation independently. However, the proposed
synergistic binding of one polypeptide by the two sites needs further investigation.
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Chapter V:
Hsc70Cb carboxyl-terminal extension is essential for fly
embryonic development
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Introduction

The proteostatic network actively protects the cell against perturbations in protein
folding and synthesis. Particularly, molecular chaperones are deployed to prevent and correct
the misfolding and aggregation of proteins in the cell. Age-related declines in proteostasis
has been linked to the onset and progression of neurodegenerative disorders like ALS,
Alzheimer’s, Parkinson’s, and Huntington’s diseases.

During aging, breakdowns in the

proteostatic network result in dysregulation of chaperone expression and changes in the cell
that make proteins more susceptible to misfolding. Additionally, declines in degradation
pathways allow misfolded protein aggregates to proliferate in the cell, leading to deleterious
effects in the cell (4, 204).

Neuronal tissues are particularly susceptible to declines in

proteostasis as these cell types are post-mitotic, and their absence from the cell cycle does
not allow for aggregate dilution through cell division (293). For this reason, it is especially
important to find therapies that addressing diseases of protein misfolding that affect the brain
and nervous system.
The previous chapter details how the carboxyl-terminus of fly (Hsc70Cb) and human
(Hsp105α and Apg-1) Hsp110s can prevent aggregation of model substrates and human
disease-linked peptides independently of the putative substrate binding domain SBD-β. This
region is conserved in metazoan species, suggesting it plays some fundamental role in
metazoan Hsp110 chaperoning. To understand whether the C-terminal extension is required
for the in vivo functions of Hsp110, I used transgenic Myc-mCherry-Hsc70Cb constructs to
rescue fruit flies from embryonic lethality mediated by two separate Hsc70Cb-null alleles.
Hsc70Cb is the sole Hsp110 chaperone in the fly genome and essential to fly embryonic
development, making it an attractive in vivo model to assess chaperone activity (220, 294,
295). The lack of other Hsp110 homologs in this species ensures the effects of mutations to
the chaperone will not be masked by the expression of a compensatory protein. The ability of
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varying Myc-mCherry-Hsc70Cb constructs to rescue from embryonic lethality will reveal
whether Hsc70Cb substrate binding is required for development.
Transgenic flies expressing Myc-mCherry-tagged Hsc70Cb constructs were created
using P-element mediated integration, allowing for random integration of tagged constructs
into the fly genome (245). Each transgene contains an upstream UAS element to facilitate
GAL4-mediated protein expression. Well established lines of GAL4-UAS drivers were used
to induce tissue-specific or ubiquitous expression of transgenic Hsc70Cb constructs in the fly
model (Figure 5-1) (246). A combination of fluorescence microscopy and phenotypic selection
markers were utilized to establish the presence and expression of fluorescent-tagged
transgene expression in vivo.
To understand the in vivo consequence of substrate binding I selected five Hsc70Cb
constructs, including the full-length chaperone, and fused an amino-terminal Myc-mCherry
tag to each. The Myc-mCherry tag was used to visualize Hsc70Cb constructs expression in
the fly system for the embryonic rescue and future disease modeling experiments. Using the
GAL4-UAS expression system I was able to constitutively express Myc-mCherry-tagged
Hsc70Cb constructs and evaluate their ability to rescue flies from embryonic lethality caused
by loss of the Hsc70Cb allele. Specifically, rescue experiments were conducted to evaluate
the essentiality of substrate binding activity to the in vivo role Hsc70Cb. Originally, this work
sought to understand how SBD-β contributes to protein aggregation in a multicellular fly
model. However, the discovery of the C-terminal extension made me ask whether or not it is
dispensable for fly survival given its potent activity in vitro. In this chapter, I show the Hsc70Cb
C-terminal extension, but not SBD-β, is essential for fly embryonic development.
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Figure 5-1: GAL4-UAS driver system allows for tissue specific expression of
transgenes in Drosophila melanogaster
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Figure 5-1: GAL4-UAS driver system allows for tissue specific expression of
transgenes in Drosophila melanogaster. This simplified mating schematic shows how
the GAL4-UAS system allows for tissue-specific expression of the GAL4 transcription factor
using a promotor of choice. GAL4 acts as a transcription activator for the UAS-sequence
upstream of the transgene, activating its expression.
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Results

To characterize the role of Hsc70Cb substrate binding in vivo I used the GAL4-UAS
expression system to drive ubiquitous or tissue-specific expression of Myc-mCherry-tagged
Hsc70Cb constructs. From my previous findings regarding Hsc70Cb, I selected chaperone
variants that lacked one or both substrate binding sites: Hsc70Cb, ΔC-term, ΔSBD-β, NBDC-term, and NBD-only (Figure 5-2). Before conducting the rescue experiments, I used the
GMR-GAL4 driver to target eye-specific expression of Hsc70Cb constructs and visually verify
the expression of Myc-mCherry-tagged chaperones, by looking for mCherry fluorescence
signal (296). Using this driver system, I was able to verify Myc-mCherry tagged Hsc70Cb
constructs are stably expressed at detectable levels in the fly (Figure 5-3).
Following expression verification, I used armadillo-GAL4 (arm-GAL4), a ubiquitous
GAL4 driver, to activate Myc-mCherry-tagged chaperone expression in flies lacking functional
Hsc70Cb (297). The Hsc70Cb gene locus is on Chromosome 3L; for the rescue experiments
null alleles replace both wild-type Hsc70Cb alleles, while maintaining a singular copy of
transgenic Myc-mCherry-Hsc70Cb on one copy of Chromosome 2 and the arm-GAL4 driver
on the other (Figure 5-4). To create flies homozygous for the Hsc70Cb null allele, BL-11485
(This strain carries a p-element insertion at the Hsc70Cb locus.) heterozygous flies were first
mated with double balancers to create a balanced BL-11485 strain. Balancing BL-11485
ensures the allele is maintained as a single copy in subsequent progeny, allowing
heterozygous flies to be selected for by the presence of a dominant marker (stubby or Sb).
Balanced BL-11485 males were mated with balanced arm-GAL4 virgin females to obtain armGAL4/Cyo; BL-11485/TM6C, Sb progeny. Theses flies were used in the final cross, providing
one copy of the BL-11485 allele and the arm-GAL4 driver for transgenic Myc-mCherryHsc70Cb (Figure 5-5). In the final rescue cross two copies of the BL-11485 allele are
introduced to the genome, replacing the endogenous Hsc70Cb alleles.
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Figure 5-2: mCherry tagged Hsc70Cb variants used in embryonic lethality rescue
experiments
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Figure 5-2: mCherry tagged Hsc70Cb variants used in embryonic lethality rescue
experiments. Five Hsc70Cb variants were selected for use in fly embryonic lethality
rescue experiments and later in vivo Huntingtin aggregation assays.

169

Figure 5-3: GMR-GAL4 driver was used to visually assess expression levels of
mCherry-tagged Hsc70Cb variants
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Figure 5-3: GMR-GAL4 driver was used to visually assess expression levels of
mCherry-tagged Hsc70Cb variants.

Transgenic UAS-mCherry-Hsc70Cb variant

encoding genes were selectively expressed in the Drosophila eye using the GMR-GAL4
driver. 7 days post-hatching flies were imaged using DSRed-filter.
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Figure 5-4: Simplified mating scheme for embryonic lethality rescue experiments
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Figure 5-4: Simplified mating scheme for embryonic lethality rescue experiments.
Male flies containing the UAS-Myc-mCherry-Hsc70Cb transgene and BL-11485 null allele
were mated with females harboring an arm-GAL4 driver and BL-11485.

Progeny

possessing arm-GAL4>UAS-Myc-mCherry-Hsc70Cb and two copies of BL-11485 were
selected for by loss of balancer chromosomes indicated by the dominant phenotypes curly
wing (CyO) and stubble hair (Sb).
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Figure 5-5: Long form mating schematic for embryonic lethality rescue experiments
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Figure 5-5: Long form mating schematic for embryonic lethality rescue experiments.
Balanced BL-11485 females (P0 – left cross) were crossed with arm-GAL4 males (P0 – left
cross) to produce balanced arm-GAL4; BL-11485 flies (F1 – left). Simultaneously, balanced
BL-11485 females (P0 – right cross) were crossed with UAS-Myc-mCherry-Hsc70Cb males
(P0 – right cross) to produce UAS-Myc-mCherry-Hsc70Cb; BL-11485 flies (F1 – right).
Balanced arm-GAL4; BL-11485 females (F2) were mated with balanced UAS-MycmCherry-Hsc70Cb; BL-11485 males (F2) to produce arm-GAL4/UAS-Myc-mCherryHsc70Cb; BL-11485/BL-11485 (F3).

175

Simultaneously, balanced UAS-Myc-mCherry-Hsc70Cb males were mated with
balanced BL-11485 virgin females to obtain UAS-Myc-mCherry-Hsc70Cb/Cyo; BL11485/TM6C progeny. The resultant progeny were mated with balanced arm-GAL4; BL11485 flies to get arm-GAL4/UAS-Myc-mCherry-Hsc70Cb; BL-11485/BL-11485 (Figure 5-5).
This final rescue cross replaces both endogenously expressed wild-type Hsc70Cb alleles with
BL-11485, and complements the loss of Hsc70Cb with arm-GAL4 driven expression of UASMyc-mCherry-Hsc70Cb transgenic constructs on Chromosome 2. Flies were selected for by
the absence of both 2nd and 3rd chromosome balancers, Cyo and TM6C, and the restoration
of a wild-type Drosophila phenotype. Loss of both balancers indicates the replacement of
endogenous Hsc70Cb with BL-11485 alleles and embryonic rescue mediated by transgenic
expression of Myc-mCherry-Hsc70Cb. Using UAS-Myc-mCherry-Hsc70Cb I was able to
rescue flies from BL-11485 embryonic lethality (4/51 flies rescued). This result confirms the
amino-terminal Myc-mCherry-tag is not occlusive to Hsc70Cb NEF function in vivo. This
rescue assay was repeated using a different Hsc70Cb null allele, L(3)S064906, and confirmed
the results obtained from using the BL-11485 allele (19/134 rescued).

Myc-mCherry-

Hsc70Cb is competent to rescue from lethality of two null alleles (Figure 5-6).
Next, I wanted to determine the role of substrate binding in the ability of Hsc70Cb to
facilitate embryonic development. To do this, I used the BL-11485 null allele and transgenic
UAS- Myc-mCherry-Hsc70Cb constructs lacking one or both substrate binding regions
highlighted previously (Figure 5-2). Repeating the rescue experiments with the remaining
Hsc70Cb constructs revealed SBD-β is dispensable for fly embryonic development (17/177
rescued), as loss of this domain does not impact Hsc70Cb activity during development (Figure
5-7). Unexpectedly, loss of the carboxyl-terminal extension, via transgenic expression of MycmCherry-Hsc70CbΔC-term, disrupts the ability of Hsc70Cb to rescue from embryonic lethality
(0/131 rescued). These results indicate the novel C-terminal extension is required for fly
development, and the SBD-β is non-essential in this process.

176

Figure 5-6: Myc-mCherry-Hsc70Cb rescues flies from two homozygous embryonic
lethal alleles
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arm-GAL4
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Figure 5-6: Myc-mCherry-Hsc70Cb rescues flies from two homozygous embryonic
lethal alleles. armadillo-GAL4 driven expression of UAS-mCherry-Hsc70Cb transgene
rescues flies from BL-11485 (L(3)00082, the Bloomington Drosophila Stock Center) and
L(3)S064906 (Szeged Drosophila Stock Centre at University of Szeged, stock # 0100467),
homozygous lethal alleles as shown by ubiquitous expression of mCherry-Hsc70Cb.
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Figure 5-7: SBD-β subdomain is expendable for fly embryonic development
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Figure 5-7: SBD-β subdomain is expendable for fly embryonic development.
armadillo-GAL4 driven expression of mCherry tagged Hsc70Cb or Hsc70CbΔSBD-β rescues
fly larvae from BL-11485 homozygous embryonic lethality. In contrast Hsc70CbΔC-term
cannot rescue from BL-11485 mediated embryonic lethality, indicating the C-terminal
extension is essential for Hsc70Cb activity and fly embryonic development (data not
shown).
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Discussion

The NEF activity of Hsp110 is a vital contributor to its in vivo activities; however, the
uncovering of a novel, conserved region in the C-terminal extension led me to investigate the
impact of various Hsp110 domains on development and survival. Using two Hsc70Cb null
alleles in the fly, I show for the first time that the novel C-terminal extension is required for fly
embryonic development. Loss of this region, via expression of Myc-mCherry-Hsc70CbΔC-term,
cannot rescue flies from BL-11485 null lethality. Furthermore, loss of the SBD-β subdomain
does not appear to have an effect on Hsc70Cb activity in vivo (Figure 5-7). The C-terminal
extension has been shown to prevent protein aggregation in vitro and the data contained
within this chapter suggests this region may also play a role in protein folding and aggregation
prevention in vivo.
It is unclear how exactly the C-terminal extension is functioning in vivo to facilitate
Hsc70Cb activities. I hypothesize the C-terminal extension is functioning similarly to what I
have shown in Chapter 4. Specifically, the IDR contained within this region is acting as a
substrate binding site, preventing the misfolding and aggregation of an unfolded polypeptide
until it is fully folded into a native conformation. This activity may occur when polypeptides
are engaged in the Hsp70 folding cycle where Hsp70, Hsp110, and unfolded substrates exist
in close proximity to one another. The interactions of unfolded substrates with the Hsp70 SBDβ and Hsp110 C-terminal extension/IDR may prevent uncontrolled movement and aberrant
interactions with other unfolded substrates. In effect, these interactions lock substrates in
place hindering their ability to misfold or be incorporated into aggregates.
One future course of study is understanding the direct role of C-terminal extension
chaperoning on a molecular level, in vivo. Schneider 2 cells (S2) are derived from Drosophila
late-stage embryonic cells that can be utilized to understand how removing the C-terminal
extension from Hsc70Cb affects protein aggregation (298). CRISPR/Cas9 can be used to
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introduce a copy of the Hsc70CbΔC-term allele into the S2 cells. RNA interference (RNAi) can
be used to suppress endogenous Hsc70Cb expression allowing Hsc70CbΔC-term to be the sole
Hsp110 chaperone in the cell. Cell lines with transgenic Hsc70CbΔC-term expression can be
transfected with a GFP-tagged reporter substrate that will be used to observe and quantify
protein aggregation in the of absence of Hsc70Cb.
This type of experiment can also be executed with mammalian cell lines using the
mouse neuronal cell line N2a. Unlike flies, mice encode two Hsp110s: Apg-1 (HSP4A) and
Hsp105α, of which Hsp105α is highly expressed in neuronal tissues (299, 300) (Figure 4-24).
For murine cell lines I propose introducing an allele encoding a Hsp105αΔC-term and using RNAi
to suppress expression of endogenous Hsp110s while observing aggregation of a reporter
substrate. Additionally, rescue experiments mimicking the one I conducted in flies can be
carried out using mice. In the mouse experiments one or both Hsp110s can be replaced with
a corresponding transgenic construct removing either SBD-β and/or the C-terminal extension.
These series of embryonic rescue experiments will reveal 1) which, if any, Hsp110 chaperone
is more essential to development in mammals and 2) if the SBD-β subdomain is expendable
for mammalian embryonic development. Although an embryonic rescue experiment cannot
be conducted using human embryos, the murine cell lines experiments I outlined can be
replicated using human cells.
The inability of Hsc70CbΔC-term to complement loss of endogenous Hsc70Cb is an
interesting finding as this construct contains NBD and the SBD-α subdomain, both required
for Hsc70Cb nucleotide exchange. In theory this construct should be able to perform Hsp110
NEF activities and potentially prevent protein aggregation in vivo via the SBD-β subdomain.
If Hsc70Cb binds unfolded substrates in vivo, it appears this activity is mediated by the Cterminal extension and the SBD-β subdomain is not essential for this function. It is unclear
why this is the case but the inability of the Hsc70CbΔC-term construct to rescue from lethality
may be due to differences in substrate binding preferences between both regions. Perhaps
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the carboxyl-terminal IDR has more promiscuous binding preferences than SBD-β, allowing
for greater propensity to prevent aggregation in vivo. An alternative explanation is the
presence of the C-terminal extension provides structural stability to Hsc70Cb; although it
appears both Hsc70CbΔC-term and Hsc70CbΔSBD-β are stable and functional in vitro. I attempted
to create a Hsc70CbΔSBD-β/ΔC-term construct but it was not stably expressed and purified from E.
coli and it is assumed to be unstable in vivo.
Like Hsc70CbΔC-term, the NBD-C-term construct does not rescue from embryonic
lethality (0/49 rescued). I imagine this result is caused by the loss of NEF activity due to the
absence of the SBD-α subdomain. Furthermore, NBD-C-term is unable to rescue despite
having the C-terminal extension, indicating this region alone is not sufficient for development.
Predictably, NBD-only does not rescue from lethality because it has neither substrate binding
capacity nor the ability to facilitate nucleotide exchange (0/21 rescued). These results indicate
nucleotide exchange, facilitated by NBD and SBD-α, and the presence of the C-terminal
extension are essential for Hsc70Cb activity during embryonic development. I speculate the
C-terminal extension is mediating substrate binding during development and/or acting as a
stabilizing region for Hsc70Cb in general.
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Chapter VI:
The C-terminal extension is a suppressor of huntingtin aggregation and
neurodegeneration in a Drosophila Huntington’s disease model
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Introduction

The accumulation of protein aggregates in the brain is a hallmark of many
neurodegenerative disorders such as ALS, Alzheimer’s, Parkinson’s, and Huntington’s
diseases. Huntington’s disease is a dominant, inherited neurodegenerative disorder caused
by the misfolding and subsequent aggregation of a mutated form of the huntingtin protein.
Huntingtin (HTT) is a large protein with a molecular weight of approximately 350 kDa with no
sequence homology to any other protein in the human genome (301). While the precise
function of HTT remains unknown, it is highly expressed in neuronal tissues and proposed to
function in the development and maintenance of neurons (301). Like humans, mice also
possess a HTT-encoding gene (Hdh); however, spontaneous Huntington’s disease is not
observed in this species (302). Nevertheless, mouse models have been used extensively to
study the potential functions of the protein in vivo. Disruption of exon 5 of Hdh results in early
embryonic lethality in homozygous mice and dysregulation of habituation in heterozygotes
when compared to controls.

Additionally, heterozygotes showed a 45% decrease in

subthalamic neurons, one of five neuron types present in the basal ganglia (303). In adult
mice Cre-Lox mediated knockout of Hdh results in gradual neurodegeneration, indicating
huntingtin plays some role in maintaining mature neurons (304).
The huntingtin encoding gene, HTT, contains a poly-glutamine encoding CAG
trinucleotide repeat that is typically less than 35 repeats in length (301, 305, 306). However,
individuals with Huntington’s disease inherit a mutated copy of HTT that has an expansion of
the CAG repeat in excess of 40 repeats. Ideally, this region is easily folded into a native
conformation; however, expansions in this region result in a HTT protein that is harder to fold
and more susceptible to assuming alternative folding patterns. Misfolded HTT acts as a
template for other unfolded HTT polypeptides causing the formation of intractable amyloid
fibrils in neuronal cells (Figure 6-1).
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Figure 6-1: Soluble and toxic folding conformations of human huntingtin
.
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Figure 6-1: Soluble and toxic folding conformations of human huntingtin. A. native
folding conformation for huntingtin. B. Mutant HTT allele contains an expanded CAG
tandem repeat (red CAG) which encodes an expanded poly-glutamine tract (depicted in
red beads and ovals). Mutant huntingtin is prone to misfolding and assuming an alternative
folding intermediate (red β-sheets). Alternative folding intermediates seed the misfolding
of soluble huntingtin which forms intractable amyloid fibrils.
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The accumulation of HTT fibrils in the brain, mainly the striatum, cortex, and basal
ganglia, leads to the onset of Huntington’s disease. Disease severity and age of onset occurs
in a CAG repeat dependent manner, with full penetrance observed in people with repeats
greater than 40. Patients with repeats exceeding 60 typically experience an earlier age of
onset and more severe symptoms. Individuals with repeats in the intermediate range of 3639 are still considered normal, but repeats in this range are unstable and more susceptible to
expansion. Individuals with intermediate alleles may develop Huntington’s disease, displaying
milder symptoms with a later age of onset. In some instances, disease does not manifest at
all but an acquired expansion can be transmitted to offspring (305, 307). CAG expansions
can occur through germline mutations or somatic cells acquiring additional repeats causing
HTT to surpass the threshold length (308).
Unlike age-dependent dementias which are more common in people over the age of
65, the typical age of onset for Huntington’s disease is around 45 years old. However, polyglutamine expansions over 60 repeats cause a juvenile form of the disease, which has an age
of onset around 20 years old (307). The highest documented CAG repeated is 250, with the
affected individual displaying symptoms at the age of two years old (309). Similar to dementia
patients, those suffering from Huntington’s disease experience memory loss, dyskinesia, and
cognitive declines. As of yet, there is no disease alleviating treatments for Huntington’s
disease, only therapies that provide some relief from disease-associated symptoms.
While Huntington’s disease is a rare genetic disorder, it provides a purely genetic
model for neurodegeneration that can be used to gain insight into the mechanisms of agerelated neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Animal models
of neurodegenerative disease shows Hsp110 expression is a strong suppressor of diseasecausing aggregation.

The anti-aggregation effects of Hsp110 activity on amyloidogenic

peptides has been demonstrated in animals modeling Parkinson’s, Alzheimer’s, ALS, and
Huntington’s diseases (118, 120, 206, 220, 221). Particularly, studies using a fruit fly model
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reveal Hsc70Cb and DnaJ-1 (Hsp40) protect against aggregation of polyQ-expanded HTT
species (220, 221). A study done by our collaborator, Dr. Sheng Zhang, demonstrated that
Hsc70Cb singularly modulates HTT aggregation in vivo (220). Moreover, ectopic expression
of Hsc70Cb strongly suppressed polyQ-expanded HTT aggregation. Flies overexpressing
Hsc70Cb are rescued from HTT fibrilization and disease-associated neurodegeneration (220).
However, the results of this study do not address what, if any, role Hsc70Cb substrate binding
has in blocking HTT aggregation.
In this chapter I attempt to elucidate the role of Hsc70Cb substrate binding activity on
preventing HTT aggregation using the same Huntington’s disease fruit fly model. GMR-GAL4
(eye-specific) driven expression of polyglutamine-expanded human HTT exon 1 was used to
model disease-associated aggregation and neurodegeneration in transgenic fruit flies.
Simultaneously, the Myc-mCherry-Hsc70Cb transgenes detailed in Chapter 5 were expressed
to supplement endogenous Hsc70Cb in this disease model. The data contained within this
chapter show the SBD-β subdomain is expendable for the anti-aggregation effects of
Hsc70Cb in an in vivo model of Huntington’s disease. Furthermore, it appears both nucleotide
exchange and substrate binding, mediated by the C-terminal extension, are required for
Hsc70Cb suppression of HTT aggregation and neurodegeneration.
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Results

To assess the role of Hsc70Cb substrate binding in a Huntington’s disease model I
utilized the previously discussed GAL4-UAS system to drive expression of transgenic HTT.
In this system I used the GMR-GAL4 driver to selectively express eGFP-tagged exon one of
human huntingtin (HTTex1-Q72-eGFP) in the fly eye, and quantify HTT aggregation. This
driver system was selected over ubiquitous or neuronal expression because it allows
observation of HTT aggregation in flies without reducing length and quality of life (310).
Simultaneously, flies co-expressed transgenic Myc-mCherry-tagged Hsc70Cb constructs in
addition to endogenous Hsc70Cb.

These assays help determine whether or not

overexpression of Hsc70Cb constructs containing either the SBD-β or the C-terminal
extension can effectively suppress HTT aggregation.
With the assistance of Dr. Shiyu Xu in the Zhang laboratory, I obtained flies coexpressing mutant HTT and Myc-mCherry-Hsc70Cb variants by mating UAS-Myc-mCherryHsc70Cb/Cyo males with GMR-GAL4>UAS-HTTex1-Q72-eGFP/Cyo virgin females, to
produce

GMR-GAL4>UAS-HTTex1-Q72-eGFP/UAS-Myc-mCherry-Hsc70Cb

progeny

(Figure 6-2a). I was able to show files expressing HTTex1-Q72-eGFP and endogenous
Hsc70Cb display a typical pattern of HTT aggregation, having numerous large HTT-eGFP foci
encompassing the entire fly eye. However, overexpression of Myc-mCherry-Hsc70Cb
reduced the size of HTT aggregates (Figure 6-3). While HTT aggregation is still present in
the Myc-mCherry-Hsc70Cb overexpression line, the aggregates are smaller in size when
compared to the control (Figure 6-3). What is most striking is overexpression of Myc-mCherryHsc70CbΔSBD-β appears to be a stronger suppressor of HTT aggregation than even MycmCherry-Hsc70Cb, causing a decrease in both the size and number of HTT aggregates when
compared to the control (Figure 6-3).

These results suggest the C-terminal extension,

specifically the IDR contained within it, modulates HTT aggregation in vivo.
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Figure 6-2: Mating schematic for in vivo aggregation and neurodegeneration
experiments

A.

B.
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Figure 6-2: Mating schematic for in vivo aggregation and neurodegeneration
experiments. A. UAS-Myc-mCherry-Hsc70Cb males (P0 – left) were crossed with GMRGAL4>UAS-HTTex1-Q72-eGFP virgin females (P0 – left) to produce flies simultaneously
expressing HTTex1-Q72-eGFP and Myc-mCherry-Hsc70Cb under the control of GMRGAL4 (F1). F1 progeny were used in the HTT aggregation experiments. B. UAS-MycmCherry-Hsc70Cb males (P0 – left) were crossed with GMR-GAL4>UAS-HTTex1-Q93
virgin females (P0 – left) to produce flies simultaneously expressing HTTex1-Q93 and MycmCherry-Hsc70Cb under the control of GMR-GAL4 (F1). F1 progeny were used in the redeye neurodegeneration experiments.
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Figure 6-3: Hsc70CbΔSBD-β suppresses huntingtin aggregation in vivo
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Figure 6-3: Hsc70CbΔSBD-β suppresses huntingtin aggregation in vivo. Respective
Myc-mCherry-Hsc70Cb constructs (or luc-RNAi) were overexpressed in flies expressing
human HTTex1-Q72-eGFP and endogenous Hsc70Cb.

Fly eyes were imaged using

fluorescence microscopy at 20x magnification 30 days post-hatching to visualize HTT
aggregation via eGFP foci formation. Control, Hsc70Cb, and Hsc70CbΔSBD-β conditions are
representative images of 10 replicates. Hsc70CbΔC-term, NBD-C-term, and NBD-only are
representative images of 3 replicates.
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To confirm the role of the far carboxy-terminus in vivo overexpression of Myc-mCherryNBD-C-term was used in the HTT aggregation model. Preliminary data from this line indicates
overexpression of NBD-C-term may suppress HTT aggregation in a similar manner to
Hsc70CbΔSBD-β; however, more replicates are needed to establish whether this is the case.
This experiment was repeated using Myc-mCherry-Hsc70CbΔC-term, and it appears this
construct also shows some anti-HTT aggregation activity in vivo but more data are needed to
come to a definitive conclusion (Figure 6-3).
In an alternative approach, I utilized the GMR-GAL4 driver to allow for eye-specific
expression of HTTex1-Q93 and overexpression of Myc-mCherry-Hsc70Cb constructs (Figure
6-2b). In this system loss of red eye pigmentation, not GFP foci formation, is used to quantify
HTT mediated neurodegeneration.

The expression of polyQ-expanded HTT causes a

disruption in the lattice structure of the ommatidia (compound eye) resulting in degeneration
of photoreceptors. HTT mediated damage to the eye causes neurodegeneration and the loss
of characteristic red-eye pigmentation (311). In this system neurodegeneration is apparent
by day 7 and becomes progressively worse until the fly eye is completely white (220). Using
this assay, I was able to show Myc-mCherry-Hsc70CbΔSBD-β overexpression suppresses
neurodegeneration, preserving the fly eye structure and red-eye pigmentation (Figure 6-4).
The Myc-mCherry-Hsc70Cb construct could not prevent neurodegeneration in this
experiment, nor did Hsc70CbΔC-term, NBD-C-term, or NBD-only constructs (Figure 6-4). Overall
both assays showed Myc-mCherry-Hsc70CbΔSBD-β suppresses HTT aggregation and
neurodegeneration, particularly in the red-eye neurodegeneration assay.
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Figure 6-4: Hsc70CbΔSBD-β suppresses huntingtin-mediated neurodegeneration in
vivo
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Figure 6-4: Hsc70CbΔSBD-β suppresses huntingtin-mediated neurodegeneration in
vivo. Respective Myc-mCherry-Hsc70Cb constructs (or luc-RNAi) were overexpressed in
flies expressing human HTTex1-Q93 and endogenous Hsc70Cb. Fly eyes were imaged
using brightfield microscopy at 20x magnification 7 days post-hatching. Control, Hsc70Cb,
and Hsc70CbΔSBD-β conditions are representative images of 10 replicates. Hsc70CbΔC-term,
NBD-C-term, and NBD-only are representative images of 3 replicates.
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Discussion

In this chapter I attempted to elucidate the role of Hsc70Cb substrate binding activity
in preventing HTT aggregation in vivo.

To do this I selected five Myc-mCherry-tagged

Hsc70Cb constructs to supplement the expression of endogenous Hsc70Cb in two fly models
of Huntington’s disease. By selectively expressing human HTT in the fly eye, I am able to
recapitulate some of the molecular effects of Huntington’s disease, specifically HTT aggregate
formation and neurodegeneration. The results of these assays demonstrate Hsc70CbΔSBD-β is
a stronger suppressor of HTT aggregation and neurodegeneration than full-length MycmCherry-Hsc70Cb. The ability of Hsc70CbΔSBD-β to prevent HTT aggregation mirrors the data
I presented in Chapters III and IV demonstrating Hsc70CbΔSBD-β is a stronger inhibitor of citrate
synthase aggregation; and the carboxy-terminal IDR prevents Aβ1-42, and α-synuclein
oligomerization in vitro.
The ability of Hsc70CbΔC-term and NBD-C-term to suppress aggregation remains
ambiguous. While both constructs appear to have fewer HTT-eGFP foci than the RNAi
control, they show no suppression activity in the red-eye neurodegeneration assays. In the
latter assay the presence of SBD-β alone is not enough to block neurodegeneration (Figure
6-3 and Figure 6-4). This result may indicate both NEF activity, which is presumed to be
absent in NBD-C-term, and substrate binding are required to suppress aggregation in vivo.
The inability of NBD-C-term to prevent aggregation supports this hypothesis, as having the
carboxy-terminal IDR, but no NEF activity due to loss of SBD-α, cannot block
neurodegeneration in the red-eye assay.
Despite reducing the size of HTT aggregates Myc-mCherry-Hsc70Cb failed to rescue
from neurodegeneration in the red-eye assays (Figure 6-3 and Figure 6-4). It is unclear why
Myc-mCherry-Hsc70Cb did not rescue from neurodegeneration, as Zhang’s study showed
weak overexpression of untagged Hsc70Cb using this same system prevented
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neurodegeneration (220). I speculate this result may be due to overactivity of Hsc70Cb NEF
activity, which has been shown to have negative effects on Hsp70 cycling and protein
aggregation (114). For the in vivo embryonic rescue and HTT aggregation experiments I used
a relatively high expression UAS-Myc-mCherry-Hsc70Cb construct (Figure 5-3). Transgenic
expression of Myc-mCherry-Hsc70Cb was successful in rescuing flies from embryonic
lethality using the ubiquitous, but low expression, armadillo-GAL4 driver.

However, the

combination of a robust driver (GMR-GAL4) and high expression UAS-Myc-mCherryHsc70Cb may have produced excessive NEF activity counteracting Hsc70Cb-mediated HTT
aggregation suppression.
These preliminary results indicate both Hsc70Cb nucleotide exchange and substrate
binding are required to suppress HTT aggregation in vivo. Further assessment of holdaseonly constructs is necessary to definitively explain the role of substrate binding in the in vivo
activities of Hsc70Cb. In future studies, an ELAV-GAL4 (neuronal) driver can be used to
assess the extent to which Hsc70CbΔSBD-β overexpression protects against the other
neurological effects of Huntington’s disease. Like human patients, flies modeling Huntington’s
disease experience motor defects as demonstrated by dysregulation of movement, disordered
geotaxis, and reduced survival (312). I predict the ability of Hsc70CbΔSBD-β to suppress HTT
aggregation and neurodegeneration will translate into the movement defects characteristic of
disease. If this is the case, overexpression of Hsc70CbΔSBD-β will protect against impaired
movement, flight, and reduced survival.

199

Chapter VII: Discussion and Future Directions
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Summary of Results

At its onset, this work sought to deconvolute the role of Hsp110 activity in preventing
protein aggregation associated with the neurodegenerative disorder Huntington’s disease.
There is extensive evidence that overexpression of Hsp110 in different neurological disease
contexts can suppress aggregation (118–120, 220, 221, 274). However, these studies did
not differentiate between the activity of Hsp110 as a co-chaperone and nucleotide exchange
factor (NEF) for Hsp70 and its independent function as a bona fide protein holdase in
mediating its anti-aggregation effects in a disease context. In this study, I sought to decouple
Hsp110 NEF activity from substrate binding activity in an attempt to decipher which function
contributes to the anti-aggregation effects of Hsp110.
I employed a Drosophila melanogaster (fruit fly) model of human Huntington’s disease
to study protein aggregation.

The fruit fly genome encodes a single copy of Hsp110,

Hsc70Cb, making it an ideal model with which to study the chaperone. Hsc70Cb possesses
the canonical Hsp110 architecture: amino-terminal nucleotide binding domain, followed by a
short linker, and a carboxy-terminal substrate binding domain containing SBD-β and SBD-α
subdomains.

Supporting results from previous work, Hsc70Cb can effectively prevent

aggregation of the model substrate, citrate synthase, in a dose-dependent manner.
Furthermore, a previous report demonstrated that modest overexpression of Hsc70Cb in a fly
model of Huntington’s disease suppressed huntingtin (HTT) mediated neurodegeneration
(220). The presence of a single Hsp110 homolog in the fly coupled with a striking visual model
of HTT aggregation and neurodegeneration made it an exemplary model to investigate in vivo
chaperone activity and how it can modulate disease.
Initially, I made systematic mutations in the putative SBD of Hsc70Cb, termed SBD-β,
and screened Hsc70Cb mutants for loss of substrate binding activity using an automated light
scatter aggregation assay. Preliminary work on Hsp110s had shown the SBD-β subdomain
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is the site of substrate binding, and mutations to this subdomain disrupt this activity (73, 74,
97, 259). I used point mutations analogous to those shown to disrupt SBD activity in the yeast
Hsp110, Sse1 (97). However, these mutations, along with additional substitutions, did not
disrupt substrate binding. Using this mutagenesis scheme, I was unable to effectively disrupt
Hsc70Cb substrate binding activity. I went on to make targeted deletions in the SBD-β
subdomain. Making deletions that removed, partially or in totality, SBD-β did not abrogate
substrate binding, a result that countered previous literature which identified SBD-β as
containing the substrate binding site in Hsp110s. Combinatorial deletion mutants were made
in which SBD-β, SBD-α, or the previously unstudied region, the C-terminal extension (C-term),
were removed from Hsc70Cb. Removal of SBD-β and SBD-α, or SBD-α and the C-terminal
extension, did not eliminate Hsc70Cb substrate binding. The NBD-C-term construct, in which
the non-chaperoning NBD is directly fused to the C-terminal extension, confirms the presence
of a substrate binding capacity in the far carboxyl-terminus of Hsc70Cb. Additionally, it
appears Hsc70CbΔSBD-β and NBD-C-term, constructs dispossessed of SBD-β, are more
effective suppressors of aggregation than full-length Hsc70Cb.
The uncovering of a substrate binding capacity in the far carboxyl-terminus led me to
investigate whether this novel region is present in other Hsp110 homologs. Using the Clustal
Omega alignment program, I was able to analyze UniProt verified sequences from a range of
Hsp110s homologs (278, 279). I found the C-terminal extension to be absent in Ascomycete
Hsp110s but present in numerous metazoan species, including human. Creating chimeric
NBD-C-term constructs I was able to show human Hsp110s also possess a substrate binding
capacity in the far carboxyl-terminus. I wanted to further localize the binding site within this
region. The crystal structure of Hsc70Cb has not been elucidated, so I relied on in silico
protein modeling to obtain a predicted structure for the C-terminal extension. Based on this
analysis, the C-terminal extension is predicted to contain three α-helices followed by a short
intrinsically disordered region (IDR). The predicted IDR was of particular interest, as IDRs
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have been shown to assume order when interacting with other proteins or polypeptides (276,
282, 313). Using an NBD-IDR construct I was able to show both fly and human IDRs can
prevent aggregation in vitro.
The conservation of the C-terminal extension in divergent eukaryotic lineages, and
some plants, led me to conclude it may be evolutionarily advantageous for many organisms
to maintain this region. After showing the C-terminal extensions can prevent aggregation of
model substrates, I wanted to know to what extent this region can also prevent aggregation
linked to neurodegenerative disease.

Using a thioflavin T binding assay I show NBD-

IDRHsc70Cb and NBD-IDRHsp105α constructs effectively suppress the oligomerization of Aβ1-42 and
α-synuclein, peptides linked to the onset and progression of Alzheimer’s and Parkinson’s
diseases, respectively. In a parallel approach, I used transmission electron microscopy to
verify the ability of NBD-IDR constructs to suppress peptide fibrilization. Interestingly, the IDR
region alone cannot suppress aggregation in these assays and requires the NBD, or another
high molecular weight protein to act as a scaffold.
To assess the function of substrate binding activities in vivo I performed an embryonic
lethality rescue experiment and modeled HTT mediated aggregation and neurodegeneration
in fruit flies. I selected five Myc-mCherry tagged Hsc70Cb constructs: Hsc70Cb, ΔC-term,
ΔSBD-β, NBD-C-term, and NBD-only and used the GAL4-UAS system to selectively or
ubiquitously express these constructs. Using an armadillo-GAL4 (ubiquitous) driver system I
was able to effectively rescue flies from Hsc70 null embryonic lethality using Myc-mCherry
tagged Hsc70Cb and Hsc70CbΔSBD-β. In the Huntington’s disease model, GMR-GAL4 was
used to selectively expression human HTTex1-Qn and overexpress Myc-mCherry tagged
Hsc70Cb constructs.

In these assays Myc-mCherry-Hsc70CbΔSBD-β was shown to be a

stronger suppressor of HTT aggregation and aggregation mediated neurodegeneration than
Myc-mCherry-Hsc70Cb. In these in vivo studies, it appears the liberation of the far C-terminal
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extension, through removal of the SBD-β, confers upon this construct an ability to suppress
and protect against HTT aggregation and neurodegeneration.
In this dissertation I show for the first time fly and human Hsp110 chaperones possess
a novel, dual substrate binding mechanism contained within the putative substrate binding
domain, SBD-β, and the previously undiscovered far C-terminal extension. Specifically, this
novel substrate binding capacity is facilitated by the presence of a short intrinsically disordered
domain (IDR) at the carboxyl-terminus of the extension. The IDRs of both fly and human
Hsp110s can suppress the oligomerization of peptides linked to human neurodegenerative
diseases in vitro. Furthermore, in vivo analysis of Hsc70Cb revealed the SBD-β subdomain
is expendable for fly embryonic development, but loss of the C-terminal extension cannot be
compensated for by the presence of SBD-β. In a disease model it appears removal of SBDβ is more protective against HTT aggregation and neurodegeneration than full-length
Hsc70Cb. While these results need further investigation, it appears the C-terminal extension
plays a distinct role in promoting embryonic development and may prevent diseaseassociated aggregation in vivo. To address the initial question this work sought to elucidate,
these data indicate both NEF activity and substrate binding activity, as mediated by the
carboxy-terminal

IDR,

are

required

to

protect

neurodegeneration.
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Novel chaperoning mechanism for metazoan Hsp110s

During the course of my investigation of Hsp110 chaperoning, I uncovered the
presence of a novel, secondary substrate binding site in the Drosophila melanogaster
Hsp110, Hsc70Cb.

This secondary site is contained within the C-terminal extension of

Hsc70Cb, and its activity is mediated by a predicted 53-amino acid intrinsically disordered
region (Figure 7-1). Using a series of thioflavin T binding assays I show the carboxy-terminal
IDR can competently prevent aggregation of amyloidogenic peptides in vitro. Furthermore,
this novel substrate binding region is present in other metazoan species, from amphibians to
great apes.

Of particular importance is the finding that IDR-mediated chaperoning is

functional in human Hsp110s, Hsp105α and Apg-1. Not only can human IDRs prevent
aggregation of the model substrate, citrate synthase, the Hsp105α IDR can suppress
oligomerization of Aβ1-42 and α-synuclein peptides in vitro. The ability of this region to prevent
amyloidogenic protein aggregation in vitro raises the question of why this region is conserved
in metazoans Hsp110 and if it has any biological significance.
While I have shown IDR-mediated substrate binding is preserved in human Hsp110s,
this region is present in a diverse array of organisms, including the fungus Cryptococcus
neoformans and the plant Arabidopsis thaliana. An interesting inquiry would be to determine
at what point Ascomycetes lost the C-terminal extension, and what evolutionary selection led
to its retention in other eukaryotes. Further analysis is needed to understand the extent to
which the carboxy-terminal IDRs in animals can prevent or suppress disease-associated
protein aggregation in vivo. The rescue experiments I conducted in fruit flies showed the Cterminal extension, and presumably the IDR contained within it, is required for fly embryonic
development. Meanwhile, the Hsp70-like substrate binding domain, SBD-β, is expendable
for development and survival. These results suggest the carboxyl-terminal IDR plays an
essential role in metazoan cells.
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Figure 7-1: Prediction of Hsc70Cb structure using AlphaFold artificial intelligence

A.

B.
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Figure 7-1: Prediction of Hsc70Cb structure using AlphaFold artificial intelligence.
A. AlphaFold was used to create a predicted structure for Drosophila melanogaster
Hsp110, Hsc70Cb, from UniProt: MM9MSL.

B. 3D-structural prediction of carboxy-

terminal IDR of Hsc70Cb done by Davi Gonçalves, PhD, using the AlphaFold source code
accompanied by prediction confidence score and IDR amino acid sequence (329).
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Present within all metazoan Hsp110s analyzed was a “XKPK”-motif in the IDR. In nonfly metazoans Hsp110s this motif presents as a PKPK-motif, while it exists as “AKPK” in flies.
I propose the residues in this motif are responsible for IDR-mediated substrate binding;
however, further analysis is required. A series of substitutions or deletions to this motif will be
sufficient to test whether substrate binding is abolished in its absence.

In addition to

identifying the residues required for IDR activity, analysis into binding preferences between
SBD-β and the IDR could further expand our understanding of Hsp110 chaperoning.
Established literature states Hsp110s preferentially bind aromatic residues in unfolded
polypeptides (249). This is in contrast to Hsp70, which prefers exposed hydrophobic residues.
The one caveat of this study is it was conducted using Sse1, the yeast Hsp110, which does
not contain a carboxy-terminal IDR making the findings specific to SBD-β. Repeating these
studies using a metazoan Hsp110 may reveal a substrate binding preference in the IDR that
is distinct from SBD-β. The structural and amino acid sequence differences between the IDR
and SBD-β would suggest the two regions have distinct mechanisms for chaperone-substrate
interaction that may translate to differential substrate preferences.
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Hsp110 IDR as a therapeutic tool

In vitro findings supporting the anti-aggregation activity of the Hsp110 IDR raises the
inquiry as to whether or not this region can be used as an effective therapeutic for human
neurodegenerative disease. Animal and cell line models of neurodegenerative diseases
confirm the role of Hsp110 chaperoning in helping to suppress aggregation and disease
progression (118–120, 206, 220, 221, 314). However, at this point it is still unclear to what
extent Hsp110 as a co-chaperone of Hsp70 or its independent functions play in mediating
these results. Kuo et al. show that Hsp110 can act with Hsp40 to suppress poly-glutamine
expanded HTT aggregation in a fly model (221). However, numerous other publications show
overexpression of Hsp110 alone is sufficient to prevent disease-associated aggregation in
Parkinson’s, Alzheimer’s, and Huntington’s disease models. What remains to be seen is the
ability to utilize chaperone intervention as a therapeutic after disease onset. While there is
strong evidence suggesting Hsp110 overexpression can suppress disease onset, there are
no studies showing how chaperone manipulation can arrest disease progression after onset.
Unlike yeast, mammalian cells do not possess a dedicated disaggregase chaperone.
In yeast the AAA+ ATPase Hsp104 plays this role by localizing to cytosolic aggregates and
disassembling them through an ATP-dependent threading mechanism (88, 315). Hsp104
activity allows liberation of unfolded polypeptides from the aggregate core, which are then
entered into the Hsp70 folding cycle to be resolubilized. In the absence of an Hsp104-like
chaperone, mammalian cells solely rely on the Hsp70-Hsp40-Hsp110 folding cycle to
dismantle protein aggregates. The Hsp70-Hsp40-Hsp110 folding cycle has been shown to
dismantle tau and α-synuclein in vitro (117, 316). While this triad can dissolve aggregates,
this activity is exceedingly slow and only energized with the addition of yeast Hsp104 or, to a
lesser extent, Hsp110 (113).
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In the mammalian disaggregase system, Hsp110 is the rate-limiting chaperone whose
relative concentration needs to be regulated in order to facilitate activity. Ex vivo studies of
mammalian disaggregation suggests it is the NEF activity of Hsp110 that drives the this
activity (113). Specifically, it appears the ability of the Hsp70 triad to disassemble preformed
aggregates requires an Hsp110 chaperone, as replacing it with non-Hsp110 NEFs does not
complement for the loss (114, 116, 216–218). This suggests Hsp110 is providing a unique,
indispensable function in the mammalian disaggregase. Initially, I presumed the presence of
a functional Hsp70-like substrate binding domain was the main feature distinguishing
Hsp110s it from other NEFs, and thus may be responsible for its crucial functions in the Hsp70
triad. However, a 2020 study by Wentink et al. showed that it may not be the substrate binding
activity of Hsp110 but its bulky size that facilities its activity against preformed aggregates
(117). The addition of SUMO and His-tags to BAG1 was sufficient to supplement for the loss
of Hsp110 in the human disaggregase, allowing for the disassembly for preformed α-synuclein
fibrils. This result indicated the size, not substrate binding activity, of Hsp110 is crucial for
Hsp70-mediated resolubilization of α-synuclein (117). Using a series of in vitro assays Mattoo
et al. showed Hsp110 can act in an ATP-dependent manner to dismantle protein aggregates,
an activity that is enhanced with the addition of Hsp40 (317). However, these results have
not been replicated by any other any studies to date.
The research showing Hsp110 NEF activity mediates its protective effects against
aggregation does not preclude the use of Hsp110 substrate binding as a potential therapeutic
for neurodegenerative disease. In this work, I show Hsc70Cb substrate binding can suppress
aggregation of amyloidogenic peptides, Aβ1-42 and α-synuclein in vitro. Additionally, I have
presented evidence suggesting this activity can suppress HTT aggregation in vivo.
Additionally, a separate finding supports Hsp110 substrate binding activity as a facilitator of
anti-aggregation in a disease context.

In this study the SBD-β and SBD-α subdomains of

Hsp105α, but not the NBD, were required to suppress aggregation of polyglutamine-expanded
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androgen receptor in a cellular model of spinal and bulbar muscular atrophy (314). Given
these results, it will be worthwhile to investigate the extent to which overexpressing Hsp110
substrate

binding

regions,

particularly

the

carboxy-terminal

IDR,

can

suppress

neurodegeneration in mammalian cells. An immediate goal would be to test overexpression
of Hsp110 IDR in a mouse or human cell line model of neurodegeneration. CRISPR/Cas9
can be used to create a transgenic cell line expression a fluorescent-tagged NBD-IDR
construct, and observing its localization to and suppression of amyloid fibrils. Additionally, an
IDR containing construct can be introduced to cells exogenously to analyze whether it can
suppress aggregation.
One important consideration is the extent to which Hsp110, or its substrate binding
derivatives, can suppress neurodegeneration in models where disease is already present. In
Chapter 4 I showed addition of NBD-IDRHsp105α to growing Aβ1-42 fibrils suppresses the
recruitment of new monomers, preventing further amyloid formation. This result suggests the
IDR may be competent to prevent progression of neurodegeneration in an in vivo disease
model. A murine model of neurodegeneration can be used to assess whether treatment with
Hsp110 IDR in early disease can arrest disease progression. If this investigation is successful
in a mouse model Hsp110 IDR therapy can be used in a clinical setting to treat human
patients. While such a therapy may not completely reverse disease, it can be used as an
early intervention tool to delay onset and progression of devastating proteinopathies.
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Future Directions

To conclude, this dissertation elucidated a novel chaperoning mechanism for
metazoan Hsp110s that utilizes a carboxy-terminal IDR. Furthermore, this IDR-mediated
substrate binding is essential for embryonic development in the fly and appears to cooperate
with Hsp110 NEF activity to suppress HTT aggregation. While this work has conferred
biological significance to the carboxyl-terminal IDR, more in-depth analysis is required to
solidify the NEF-independent activities of Hsp110 in vivo. Hopefully the research I have
presented here will lay a strong foundation upon which to further study Hsp110 chaperoning
and its role in human neurodegenerative disease.
An immediate future goal for this research is to investigate the degree to which IDR
expression can suppress symptoms associated with neurodegenerative disease. While it has
been shown that Hsp110 can suppress aggregation, and even halt lengthening of amyloid
fibrils, it is unclear whether arresting amyloid formation corresponds to a cessation of
symptoms. Fruit flies can be used to answer these questions, as they present with symptoms
similar to those experienced by Huntington’s disease patients. Transgenic flies with ELAVGAL4 (neuronal) driven expression of eGFP-tagged human HTT and doxycycline-inducible
expression of Hsc70Cb, or NBD-IDR, can be used to for these assays (318). Flies can be
scored for HTT aggregation via eGFP foci formation and defects in motor movements, as
measured by previously established climbing and flight assays at specified intervals after
hatching (319). Doxycycline induced expression of Hsc70Cb or NBD-IDR can be employed
as a treatment. Doxycycline treated flies will be assessed for HTT aggregation and defects
in motor movements and compared to wild-type flies and non-treated flies to assess how
effective Hsc70Cb intervention is at halting disease.
An important course of study is to investigate how Hsp110 induction can prevent,
arrest, or even reverse neuronal damage in disease. There are many studies showing
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Hsp110 suppresses protein aggregation in disease; however, human patients already have
aggregate accumulation and disease phenotypes when they come for treatment.

To

understand the therapeutic value of Hsp110 mammalian cell line, neuronal organoids, and
murine models of disease should be employed were Hsp110 is delivered to cells after disease
has manifested on a molecular level. In the case of animal models, the use of a blood-brain
barrier (BBB) permeable vector is required for adequate drug delivery and treatment. To this
end, adenoviruses used for gene therapy can be employed for delivery of Hsp110 or, its
substrate binding derivates, to diseased brains. Furthermore, the potential findings from these
studies can be applied to other neurological ailments, as there is evidence to suggest Hsp110
therapy may be a viable option for patients who suffered a traumatic brain injury or stroke
(320). Additionally, advances in drug design have introduced nanoparticles and nanovesicles
as an effective tool for drug delivery to the brain (321–323). These therapies are BBB
permeable and can be targeted to amyloid sites using markers of neuroinflammation for
localization.
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